自己免疫性脳炎・関連疾患ハンドブック

出版社： 金芳堂
著者：
発行日： 2023-05-01
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784765319560
電子書籍版： 2023-05-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,920 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,920 円(税込)

購入する

商品紹介

睡眠病、認知症、精神症状の原因も自己免疫性脳炎だった？　治療可能な見過ごされている疾患、自己免疫性脳炎の本邦初のハンドブック

目次

  • I　総論
    　1　定義・歴史・展望
    　2　自己免疫性脳炎の疫学と特徴
    　3　自己免疫性脳炎の診断・検査の進め方
    　4　自己免疫性脳炎・脳症の治療
    　5　抗神経抗体の分類と病態（細胞内抗原抗体vs細胞表面抗原抗体）
    　6　傍腫瘍性神経症候群関連自己抗体の分類と病態

    II　自己免疫性脳炎·脳症の主な臨床病型
    　1　抗NMDAR脳炎
    　2　自己免疫性辺縁系脳炎
    　3　視神経脊髄炎スペクトラム障害（NMOSD）
    　4　MOG抗体関連疾患（MOGAD）
    　5　抗LGI1脳炎・抗Caspr2脳炎
    　6　Bickerstaff脳幹脳炎
    　7　橋本脳症
    　8　自己免疫性GFAPアストロサイトパチー
    　9　IgLON5抗体関連疾患
    　10　DPPX抗体関連脳炎
    　11　抑制性シナプスに対する自己免疫疾患
    　12　Sez6l2抗体関連脳炎
    　13　KLHL11抗体関連脳炎

    III　神経・精神疾患と自己免疫
    　1　自己免疫性認知症
    　2　自己免疫性精神病
    　3　自己免疫性てんかん
    　4　自己免疫性小脳失調症（傍腫瘍性小脳変性症）
    　5　自己免疫性小脳失調症（抗神経抗体を伴う非傍腫瘍性小脳性運動失調症）
    　6　自己免疫性運動異常症
    　7　自己免疫性睡眠異常症
    　8　自己免疫性自律神経節障害
    　9　免疫チェックポイント阻害薬と自己免疫性脳炎
    　10　小児の自己免疫性脳炎

    IV　自己抗体一覧
    　1　細胞表面抗原抗
    　2　細胞内抗原抗体

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.11 掲載の参考文献
1. Dalmau, J., & Graus, F. (2022). Deconstructing Hashimoto Encephalopathy. In Autoimmune Encephalitis and Related Disorders of the Nervous System (pp.460-475). Cambridge: Cam-bridge University Press. doi:10. 1017/9781108696722. 018
 
2. Dalmau J, et al. Antibody-mediated encephalitis. N Engl J Med 2018; 378: 840-851.
PubMed
3. Corsellis JA, et al. 'Limbic encephalitis' and its association with carcinoma. Brain 1968; 91: 481-496.
PubMed
4. Arino H, et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol 2015; 72: 874-881.
PubMed
5. Do LD, et al. Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibod-ies. Neurology 2017; 88: 514-524.
 
6. Wilkinson PC, et al. Immunofluorescent detection of antibodies against neurons in sensory carcinomatous neuropathy. Brain 1965; 88: 529-538.
PubMed
7. Graus F, et al. Sensory neuronopathy and small cell lung cancer: antineuronal antibody thet also reacts with the tumor. Am J Med 1986; 80: 45-52.
 
8. Trotter JL, et al. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol 1976; 33: 660-661.
PubMed
9. Graus F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74: 55-61.
PubMed
10. de Graaff E, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71: 815-824.
PubMed
11. Greenlee JE, et al. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983; 14: 609-613.
PubMed
12. Tanaka M, et al. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg 1995; 97: 95-100.
 
13. Lee EK, et al. Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry 1998; 65: 857-862.
PubMed
14. Liguori R, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124: 2417-2426.
 
15. Vincent A, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712.
PubMed
16. Lai M, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785.
PubMed
17. Irani SR, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748.
 
18. 西村敏樹, ほか. 無菌性非ヘルペスウイルス性急性脳炎の病態-若年女性に起こり, 強い意識障害と遷延性経過を示すが転帰比較的良好な1群について-. Neuroinfection 1997; 2: 74-76.
 
19. Vitaliani R, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58: 594-604.
PubMed
20. Dalmau J, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
PubMed
21. Lai M, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434.
PubMed
22. Fuseya K, et al. Corticobasal Syndrome in a Patient with Anti-IgLON5 Antibodies. Mov Disord Clin Pract. 2020; 7: 557-559.
 
23. Takeoshi A, et al. Clinical Features and Neuroimaging Findings of Neuropil Antibody-Positive Idiopathic Sporadic Ataxia of Unknown Etiology. Cerebellum. 2022 Sep 3. doi: 10. 1007/s12311-022-01468-3.
 
24. JPRN Search Portal. 臨床研究計画実施番号 jRCTs031200250(https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs031200250)
 
25. Chong JY, et al. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003; 60: 164-171.
PubMed
26. Castillo P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63: 197-202.
PubMed
27. 下畑享良, ほか. 抗IgLON5抗体関連疾患の臨床像. 臨床神経 2021; 61: 825-832.
 
P.21 掲載の参考文献
1. 大石真莉子, ほか. :自己免疫性脳炎の全国調査. 厚労省科研費新エビデンス班会議抄録集. 2020.
 
2. Granerod J, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010; 10: 835-844.0
 
3. Granerod J, et al. New estimates of incidence of encephalitis in England. Emerg Infect Dis. 2013; 19: 1455-1462.
 
4. Dubey D, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018; 83: 166-177.
 
5. Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013; 12: 157-165.
PubMed
6. Titulaer MJ, et al. Authors' reply. Lancet Neurol. 2013; 12: 425-426.
PubMed
7. Arino H, et al. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology 2016; . 87: 759-765.
PubMed
8. Chong JY, et al. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003; 60: 164-171.
PubMed
9. Chaudhuri A, et al. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimo-to's encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem. 2003; 10: 1945-1953.
 
10. Castillo P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006; 63: 197-202.
PubMed
P.28 掲載の参考文献
1. Dalmau J, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61: 25-36.
PubMed
2. Dalmau J, et al. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev. 2017; 97: 839-887.
PubMed
3. Dalmau J, et al. Antibody-Mediated Encephalitis. N Engl J Med. 2018; 378: 840-851.
PubMed
4. Hara M, et al. Practical approach for the diagnosis of disorders associated with antibodies against neuronal surface proteins. Neurol Clin Neurosci 2020; 9: 56-62.
 
5. Singh TD, et al. Postencephalitic epilepsy: clinical characteristics and predictors. Epilepsia. 2015; 56: 133-138.
PubMed
6. Wagner JN, et al. Evaluation of Clinical and Paraclinical Findings for the Differential Diagno-sis of Autoimmune and Infectious Encephalitis. Front Neurol. 2018; 9: 434.
 
7. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15: 391-404.
PubMed
8. Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004; 75: 1135-1140.
PubMed
9. Hoftberger R, et al. Clinical neuropathology practice guide 5-2012: updated guideline for the diagnosis of antineuronal antibodies. Clin Neuropathol. 2012; 31: 337-341.
PubMed
10. Hoftberger R. Neuroimmunology: an expanding frontier in autoimmunity. Front Immunol. 2015; 6: 206.
PubMed
11. Ruiz-Garcia R, et al. Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis. Front Immunol. 2021; 12: 691536.
PubMed
12. Hara M, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology. 2018; 90: e1386-e1394.
PubMed
13. 原 誠, ほか. 自己免疫性脳炎の臨床における最近の進歩. 臨免疫・アレルギー科 2022; 77: 456-463.
 
14. Dalmau J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychia-trists: mechanisms and models. Lancet Neurol. 2019; 18: 1045-1057.
 
15. van Sonderen A, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016; 87: 1449-1456.
PubMed
16. Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. J Clin Neurol 2016; 12: 1-13.
PubMed
17. Hara M, et al. : DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology 2017; 88: 1340-1348.
PubMed
18. 飯塚高浩. 自己免疫性脳炎およびその類縁疾患における最近の進歩. 臨床神経 2019; 59: 491-501.
 
19. 原 誠, ほか. 自己免疫性脳炎の臨床における最近の動向. 臨免疫アレルギー科 2020; 74: 364-372.
 
20. Bastiaansen AEM, et al. Autoimmune Encephalitis Resembling Dementia Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021; 8: e1039.
PubMed
P.40 掲載の参考文献
1. Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurosurg Psychiatry 2004; 75: 1135-1140.
 
2. Vedeler CA, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13: 682-690.
PubMed
3. Titulaer MJ, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18: 19-e3.
 
4. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
5. Abboud H, et al. Autoimmune encephalitis: proposed best practice recommendations for diag-nosis and acute management. J Neurol Neurosurg Psychiatry 2021; 92: 757-768.
 
6. Nosadini M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1052.
PubMed
7. Dalmau J, et al. Autoimmune Encephalitis and Related Disorders of the Nervous System: Cam-bridge University Press; 2022.
 
8. Russell DS. Encephalomyelitis and 'carcinomatous neuropathy'. 1961. In: L. van Bogaert, et al (eds). Encephalitides: Elsevier; 1961.
 
9. Darnell RB, et al. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-1554.
PubMed
10. Kawachi I. Systematic approach to diagnosis of paraneoplastic neurological syndromes. Nihon Naika Gakkai zasshi 2008; 97: 1823-1829.
PubMed
11. Vincent A, et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759-772.
PubMed
12. Graus F, et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunolog-ic associations. Neurology 2008; 71: 930-936.
 
13. Graus F, et al. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257: 509-517.
PubMed
14. Wanschitz J, et al. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morpho-logic study. Neurology 1997; 49: 1156-1159.
 
15. Voltz R, et al. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998; 51: 1146-1150.
PubMed
16. Albert ML, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4: 1321-1324.
PubMed
17. Roberts WK, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119: 2042-2051.
PubMed
18. Dalmau J, et al. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev 2017; 97: 839-887.
PubMed
19. Dalmau J, et al. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-340.
PubMed
20. Graus F, et al. Paraneoplastic neurological syndromes. Curr Opin Neurol 2012; 25: 795-801.
PubMed
21. Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture. Neurology 2016; 87: 2471-2482.
PubMed
22. Graus F, et al. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019; 16: 535-548.
PubMed
23. 河内 泉. 自己免疫性脳炎・脳症: 東京: 医学書院; 2022.
 
24. Petrillo MG, et al. Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids. BMC Pharmacol Toxicol 2014; 15: 35.
 
25. Tsitoura DC, et al. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest 2004; 113: 619-627.
PubMed
26. Leussink VI, et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001; 58: 91-97.
PubMed
27. Jones SA, et al. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus. Ann Rheum Dis 2016; 75: 739-747.
PubMed
28. Kamhieh-Milz J, et al. Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP). Clin Immunol 2018; 188: 74-80.
PubMed
29. Lim HY, et al. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007; 122: 47-53.
PubMed
30. 小谷 俊雄, ほか. γグロブリン大量静注療法. 日内会誌 2009; 98: 2512-2517.
 
31. Vani J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmu-nity Rev 2008; 7: 440-444.
 
32. Nimmerjahn F, et al. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-533.
PubMed
33. Schwartz J, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evi-dence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31: 149-162.
 
34. DeSena AD, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: A retrospective review. J Clin Apher 2015; 30: 212-216.
 
35. Pham HP, et al. Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis. J Clin Apher 2011; 26: 320-325.
PubMed
36. 三森経世. 免疫抑制薬の選び方と使い方: 南江堂; 2000.
 
37. 川合眞一. 抗リウマチ薬の選び方と使い方: 南江堂; 2006.
 
38. Wang T, et al. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-as-partate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observa-tional study. J Neuroimmunol 2021; 354: 577527.
 
39. Dinoto A, et al. Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review. J Neuroimmunol 2021; 356: 577586.
 
40. Lee WJ, et al. Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institu-tional Cohort Study. Neurotherapeutics 2016; 13: 824-832.
 
41. Lee WJ, et al. Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis. Neurotherapeutics 2021; 18: 474-487.
PubMed
42. Dalmau J, et al. Clinical experience and laboratory investigations in patients with an-ti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
 
43. Nosadini M, et al. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspar-tate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol 2021; 78: 1333-1344.
 
44. Balu R, et al. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 2019; 92: e244-e252.
PubMed
45. Dalmau J, et al. Antibody-Mediated Encephalitis. N Engl J Medi 2018; 378: 840-851.
 
46. 河内 泉. 【Antibody Update 2018】傍腫瘍性神経症候群と自己抗体. Brain Nerve 2018; 70: 0329-0339.
 
47. Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes Neurol Neuroimmunol Neuroinflamm 2021;8:e1014.
PubMed
P.51 掲載の参考文献
1. Dalmau J, et al. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev 2017; 97: 839-887.
PubMed
2. Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1014.
PubMed
3. Armangue T, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encepha-litis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17: 760-772.
 
4. Graus F, et al. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019; 16: 535-548.
PubMed
5. Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140.
PubMed
6. Greenlee JE, et al. Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation 2014; 11: 160.
 
7. Greenlee JE, et al. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneo-plastic cerebellar degeneration in humans with gynecological or breast cancers. PLoS One 2015; 10: e0123446.
PubMed
8. Sommer C, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005; 365: 1406-1411.
PubMed
9. Geis C, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010; 133: 3166-3180.
PubMed
10. Poh MQ, et al. Evidence of T-cell mediated neuronal injury in stiff-person syndrome with anti-amphiphysin antibodies. J Neurol Sci 2014; 337: 235-237.
PubMed
11. Clouston PD, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 1992; 42: 1944-1950.
PubMed
12. Sillevis Smitt P, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342: 21-27.
PubMed
13. Vincent A, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712.
PubMed
14. Dalmau J, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
PubMed
15. Planaguma J, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015; 138: 94-109.
 
16. Sprengel R. Role of AMPA receptors in synaptic plasticity Cell Tissue Res 2006; 326: 447-455.
PubMed
17. Lai M, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434: 2009.
 
18. Peng X, et al. Cellular plasticity induced by anti-alphaα-amino-3-hydroxy-5-methyl-4-isox-azolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 2015; 77: 381-398.
 
19. Haselmann H, et al. Human Autoantibodies against the AMPA Receptor Subunit GluA2 Induce Receptor Reorganization and Memory Dysfunction. Neuron 2018; 100: 91-105. e9.
 
20. Lancaster E, et al. Antibodies to the GABA (B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76.
 
21. Irani SR, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748.
 
22. Fukata Y, et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006; 313: 1792-1795.
PubMed
23. Fukata Y, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic trans-mission and epilepsy. Proc Natl Acad Sci USA 2010; 107: 3799-3804.
 
24. Kalachikov S, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002; 30: 335-341.
PubMed
25. Yu YE, et al. Lgi1 null mutant mice exhibit myoclonic seizures and CA1 neuronal hyperexcit-ability. Hum Mol Genet 2010; 19: 1702-1711.
 
26. Huijbers MG, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol 2015; 22: 1151-1161.
PubMed
27. Ohkawa T, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013; 33: 18161-18174.
PubMed
28. Petit-Pedrol M, et al. LGI1 antibodies alter Kv1. 1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain 2018; 141: 3144-3159.
PubMed
29. Traka M, et al. Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J Cell Biol 2003; 162: 1161-1172.
PubMed
30. Giannoccaro MP, et al. Behaviour and neuropathology in mice injected with human contac-tin-associated protein 2 antibodies. Brain 2019; 142: 2000-2012.
 
31. Ichise T, et al. mGluR1 in cerebellar Purkinje cells essential for long-term depression, synapse elimination, and motor coordination. Science 2000; 288: 1832-1835.
PubMed
32. Conquet F, et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 1994; 372: 237-243.
PubMed
33. Spatola M, et al. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology 2020; 95: e3012-e3025.
PubMed
34. Sillevis Smitt P, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342: 21-27.
PubMed
35. Macdonald RL, et al. GABAA receptor channels. Annu Rev Neurosci 1994; 17: 569-602.
PubMed
36. Rudolph U, et al. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011; 10: 685-697.
PubMed
37. Sigel E, et al. Structure, function, and modulation of GABA (A) receptors. J Biol Chem 2012; 287: 40224-40231.
PubMed
38. Petit-Pedrol M, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13: 276-286.
 
39. Nadal MS, et al. The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K channels. Neuron 2003; 37: 449-461.
 
40. Piepgras J, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology 2015; 85: 890-897.
PubMed
41. Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008; 455: 903-911.
PubMed
42. Gauthier J, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet 2011; 130: 563-573.
PubMed
43. Gresa-Arribas N, et al. Human neurexin-3αalpha antibodies associate with encephalitis and alter synapse development. Neurology 2016; 86: 2235-2242.
 
44. Karagogeos D. Neural GPI-anchored cell adhesion molecules. Front Biosci 2003; 8: s1304-1320.
PubMed
45. Sabater L, et al. Cellular investigations with human antibodies associated with the anti-Ig-LON5 syndrome. J Neuroinflammation 2016; 13: 226.
 
46. Landa J, et al. Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. Ann Neurol 2020; 88: 1023-1027.
PubMed
47. Ryding M, et al. Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons. Cells 2021; 10: 837.
PubMed
48. Alvente S, et al. Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice. Cells 2022; 11: 1024.
PubMed
49. Flanagan EP, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoim-mune astrocytopathy: Analysis of 102 patients. Ann Neurol 2017; 81: 298-309.
 
50. Gaig C, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017; 88: 1736-1743.
PubMed
P.62 掲載の参考文献
1. Graus F, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1014.
PubMed
2. Vogrig A, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 2020; 267: 26-35.
PubMed
3. van Sonderen A, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87: 1449-1456.
PubMed
4. Lancaster E. Autoantibody encephalitis: presentation, diagnosis, and management. J Clin Neurol 2022; 18: 373-390.
PubMed
5. Tanaka K, et al. Significance of Autoantibodies in Autoimmune Encephalitis in Relation to Antigen Localization: An Outline of Frequently Reported Autoantibodies with a Non-System-atic Review. Int J Mol Sci 2020; 21: 4941.
PubMed
6. Dubey D, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 2018; 90: e103-110.
PubMed
7. Hoffmann LA, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79: 767-773.
 
8. De Camilli P, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoan-tigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993; 178: 2219-2223.
 
9. Pittock SJ, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58: 96-107.
PubMed
10. Luque FA, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29: 241-251.
PubMed
11. Pittock SJ, et al. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53: 580-587.
PubMed
12. Feldheim J, et al. Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies. Neurol Res Pract 2021; 3: 30.
PubMed
13. Dechelotte B, et al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2020; 7: e701.
PubMed
14. Rosenfeld MR, et al. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 2013; 14: 528-538.
PubMed
15. Tanaka K, et al. Trial of cytotoxic T cell induction in mice as an ex vivo model of paraneoplas-tic neurologic syndrome with anti-Hu antibodies. Clin Exp Neuroimmunol 2022.
 
16. Small M, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol 2018; 135: 569-579.
 
17. Rojas-Marcos I, et al. Human epidermal growth factor receptor 2 overexpression in breast can-cer of patients with anti-Yo-associated paraneoplastic cerebellar degeneration. Neuro Oncol 2012; 14: 506-510.
 
18. Vialatte de Pemille C, et al. Transcriptomic immune profiling of ovarian cancers in paraneo-plastic cerebellar degeneration associated with anti-Yo antibodies. Br J Cancer 2018; 119: 105-113.
 
19. Chefdeville A, et al. Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D- aspartate receptor encephalitis. Acta Neuropathol Commun 2019; 7: 38.
PubMed
20. Day GS, et al. Abnormal neurons in teratomas in NMDAR encephalitis. JAMA Neurol 2014; 71: 717-724.
PubMed
21. Makuch M, et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications. Ann Neurol 2018; 83: 553-561.
PubMed
22. Tani T, et al. Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 2008; 196: 166-169.
PubMed
23. Gill A, et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol 2019; 334: 576980.
 
24. Nakayama A, et al. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma. PLoS One 2019; 14: e0211358.
PubMed
25. Ishigaki K, et al. HLA autoimmune risk alleles restrict the hypervariable region of T cell receptors. Nat Genet 2022; 54: 393-402.
PubMed
26. Jitprapaikulsan J, et al. Paraneoplastic neurological syndrome: an evolving story. Neurooncol Practice 2021; 8: 362-374.
 

II 自己免疫性脳炎・脳症の主な臨床病型

P.74 掲載の参考文献
1. Dalmau J, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
PubMed
2. Vitaliani R, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58: 594-604.
PubMed
3. Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
PubMed
4. Dalmau J, et al. Clinical experience and laboratory investigations in patients with an-ti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
 
5. Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165.
PubMed
6. Dalmau J, et al. Antibody-Mediated Encephalitis. N Engl J Med 2018; 378: 840-851.
PubMed
7. Gable MS, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012; 54: 899-904.
PubMed
8. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
9. Kaneko A, et al. Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis. J Neurol 2018; 265: 586-596.
PubMed
10. Iizuka T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008; 70: 504-511.
PubMed
11. Tominaga N, et al. Prodromal headache in anti-NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity. Brain Behav 2018; 8: e01012.
PubMed
12. Guasp M, et al. Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psycho-sis. Neurology 2021; 97: e61-e75.
 
13. Schmitt SE, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA recep-tor encephalitis. Neurology 2012; 79: 1094-1100.
 
14. Titulaer MJ, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-428.
PubMed
15. Iizuka T, et al. Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis. JAMA Neurol 2016; 73: 706-713.
PubMed
16. Tuzun E, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009; 118: 737-743.
PubMed
17. Martinez-Hernandez E, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011; 77: 589-593.
PubMed
18. Zrzavy T, et al. Neuropathological variability within a spectrum of NMDAR-encephalitis. Ann Neurol 2021; 90: 725-737.
PubMed
19. Makuch M, et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications. Ann Neurol 2018; 83: 553-561.
PubMed
20. Armangue T, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encepha-litis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17: 760-772.
 
21. Hara M, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology 2018; 90: e1386-e1394.
PubMed
22. Heine J, et al. Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Ann Neurol 2021; 90: 949-961.
PubMed
23. Nosadini M, et al. Use and Safety of Immunotherapeutic Management of N-methyl-d-Aspar-tate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol 2021; 78: 1333-1344.
 
24. Steriade C, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia 2020; 61: 1341-1351.
PubMed
25. Nosadini M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1052.
PubMed
P.102 掲載の参考文献
1. Greenlee JE, et al. Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis. Front Neurol 2022; 12: 744653.
PubMed
2. Brierley JB, et al. Subacute encephalitis of later adult life. Mainly affecting the limbic areas. Brain 1960; 83: 357-368.
 
3. Corsellis JA, et al. "Limbic encephalitis" and its association with carcinoma. Brain 1968; 91: 481-496.
PubMed
4. Vital C, et al. Paraneoplastic limbic encephalitis. Anatomo-clinical study of 2 cases. Arch Anat Pathol (Paris) 1973; 21: 279-285.
PubMed
5. Roxo MR, et al. The limbic system conception and its historical evolution. ScientificWorld-Journal 2011; 11: 2428-2441.
PubMed
6. 湯浅龍彦, ほか. 辺縁系脳炎-歴史, 症状, 最新分類. Brain Nerve 2010; 62: 817-826.
 
7. 飯塚高浩. 自己免疫性脳炎およびその類縁疾患における最近の進歩. 臨神経 2019; 59: 491-501.
 
8. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
9. Bien CG. Limbic encephalitis. Handb Clin Neurol 2022; 187: 467-487.
PubMed
10. Dalmau J, et al. Antibody-Mediated Encephalitis. N Engl J Med 2018; 378: 840-851.
PubMed
11. Liu R, et al. Neuronal Surface Antibody Syndrome: A Review of the Characteristics of the Disease and Its Association with Autoantibodies. Neuroimmunomodulation 2020; 27: 1-8.
PubMed
12. 厚生労働省. 第8回障害者総合支援法対象疾病検討会. 自己免疫介在性脳炎・脳症 https://www.mhlw.go.jp/content/12201000/000828398.pdf
 
13. Kaneko J, et al. Practical issues in measuring autoantibodies to neuronal cell-surface antigens in autoimmune neurological disorders: 190 cases. J Neurol Sci 2018; 390: 26-32.
 
14. Honnorat J, et al. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2: 22.
PubMed
15. de Beukelaar JW, et al. Managing paraneoplastic neurological disorders. Oncologist 2006; 11: 292-305.
PubMed
16. Lai M, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434.
PubMed
17. van Sonderen A, et al. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol 2017; 13: 290-301.
PubMed
18. Vincent A, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712.
PubMed
19. Gadoth A, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 2017; 82: 79-92.
PubMed
20. Malter MP, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephali-tis. Ann Neurol 2010; 67: 470-478.
 
21. Bien CG, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135: 1622-1638.
PubMed
22. van Sonderen A, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87: 1449-1456.
PubMed
23. Ohkawa T, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013; 33: 18161-18174.
PubMed
24. Binks SNM, et al. LGI1, CASPR2 and related antibodies: a molecular evolution of the pheno-types. J Neurol Neurosurg Psychiatry 2018; 89: 526-534.
 
25. Binks S, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain 2018; 141: 2263-2271.
PubMed
26. Blinder T, et al. Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis. Front Neurol 2019; 10: 804.
PubMed
27. Malter MP, et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol 2014; 261: 1695-1705.
PubMed
28. Lancaster E, et al. Antibodies to the GABA (B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76.
 
29. Ronchi NR, et al. Comparison of the clinical syndromes of anti-GABAa versus anti-GABAb associated autoimmune encephalitis: A systematic review. J Neuroimmunol 2022; 363: 577804.
PubMed
30. Lancaster E, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syn-drome. Neurology 2011; 77: 1698-1701.
 
31. Carvajal-Gonzalez A, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014; 137: 2178-2192.
PubMed
32. Zekeridou A, et al. Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1. Ann Neurol 2022; 91: 670-675.
PubMed
33. Honnorat J, et al. Are the "newly discovered" paraneoplastic anticollapsin response-mediator protein 5 antibodies simply anti-CV2 antibodies? Ann Neurol 2001; 50: 688-691.
PubMed
34. Voltz R, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340: 1788-1795.
PubMed
35. Pittock SJ, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58: 96-107.
PubMed
36. Arino H, et al. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. JAMA Neurol 2015; 72: 874-881.
PubMed
37. Tuzun E, et al. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol 2007; 186: 177-180.
PubMed
38. Bien CI, et al. Identification of adenylate kinase 5 antibodies during routine diagnostics in a tissue-based assay: Three new cases and a review of the literature. J Neuroimmunol 2019; 334: 576975.
 
39. Brain L, et al. Hashimoto's disease and encephalopathy. Lancet 1966; 2: 512-514.
PubMed
40. Shaw PJ, et al. Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers: report of 5 cases. Neurology 1991; 41: 228-233.
PubMed
41. Fujii A, et al. Autoantibodies against the amino terminal of alpha -enolase are a useful diag-nostic marker of Hashimoto's encephalopathy. J Neuroimmunol 2005; 162: 130-136.
 
42. Kishitani T, et al. Limbic encephalitis associated with anti-NH2-terminal of α-enolase antibodies: A clinical subtype of Hashimoto encephalopathy. Medicine (Baltimore) 2017; 96: e6181.
 
43. Mattozzi S, et al. Hashimoto encephalopathy in the 21st century. Neurology 2020; 94: e217-e224.
PubMed
44. Hirsch LJ, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018; 59: 739-744.
PubMed
45. Yanagida A, et al. Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Neurol Neuroimmunol Neuroinflamm 2020; 7: e849.
PubMed
46. Mughal AA, et al. Patterns of invasive growth in malignant gliomas-The hippocampus emerges as an invasion-Spared brain region. Neoplasia 2018; 20: 643-656.
PubMed
47. Phi JH, et al. Brain tumors in the mesial temporal lobe: long-term oncological outcome. Neurosurg Focus 2009; 27: E5.
PubMed
48. Zoccarato M, et al. Conventional brain MRI features distinguishing limbic encephalitis from mesial temporal glioma. Neuroradiology 2019; 61: 853-860.
PubMed
49. 金光宗一, ほか. 両側視床病変が遅発性に出現した悪性リンパ腫関連傍腫瘍性辺縁系脳炎の1例. Brain Nerve 2012; 64: 71-77.
 
50. Oyanguren B, et al. Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol 2013; 20: 1566-1570.
PubMed
51. 黒田 宙. 単純ヘルペス脳炎update. Brain Nerve 2015; 67: 931-939.
 
52. Maes L, et al. Acute autonomic dysregulation due to HHV-6 encephalitis in an immunocom-promised patient: a case report and literature review. 2022; 122: 583-585.
 
53. 新村浩透, ほか. シェーグレン症候群に合併した急性辺縁系脳炎の1例. Brain Nerve 2016; 68: 567-571.
 
54. Collison K, et al. Asymmetric cerebellar ataxia and limbic encephalitis as a presenting feature of primary Sjogren's syndrome. J Neurol 2007; 254: 1609-1611.
PubMed
55. 中島 綾, ほか. 抗核抗体と抗SS-A抗体が強陽性で髄液中に抗神経抗体をみとめた非ヘルペス性, 非傍腫瘍性辺縁系脳炎の1剖検例. 臨神経 2005;45:100-104.
 
56. da Rocha AJ, et al. Recognizing autoimmune-mediated encephalitis in the differential diagnosis of limbic disorders. AJNR Am J Neuroradiol 2015; 36: 2196-2205.
PubMed
57. Tan KM, et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurolo-gy 2008; 70: 1883-1890.
 
58. Geschwind MD, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob Disease. Arch Neurol 2008; 65: 1341-1346.
PubMed
59. Rossi M, et al. Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2015; 86: 692-694.
PubMed
60. Benoit Dechelotte, , et al. Diagnostic yield of commercial immunodots to diagnose paraneo-plastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2020; 7: e701.
 
61. Gresa-Arribas N, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis, a retrospective study. Lancet Neurol 2014; 13: 167-177.
PubMed
62. Urbach H, et al. Serial MRI in patients with acquired hippocampal sclerosis. Clin Neuroradiol 2006; 16: 47-52.
 
63. Kotsenas AL, et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 2014; 35: 84-89.
PubMed
64. 望月葉子, ほか. 非ヘルペス性辺縁系脳炎の病理. Brain Nerve 2010; 62: 861-868.
 
65. Malviya M, et al. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody. Ann Clin Transl Neurol 2017; 4: 768-783.
 
66. Martinez-Hernandez E, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011; 77: 589-593.
PubMed
67. Hughes EG, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30: 5866-5875.
PubMed
68. 大阪大学大学院医学系研究科 呼吸器・免疫内科学. 免疫疾患の解説: IgG4関連疾患IgG4-related disease. http://www.imed3.med.osaka-u.ac.jp/disease/d-immu07-3.html
 
69. Uy CE, et al. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol 2021; 21: 412-423.
PubMed
70. Dalmau J, et al. Clinical experience and laboratory investigations in patients with an-ti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
 
71. Dubey D, et al. Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Ann Neurol 2020; 87: 313-323.
PubMed
72. Nosadini M, et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother 2015; 15: 1391-1419.
PubMed
73. Dinoto A, et al. Treatment Options in Refractory Autoimmune Encephalitis. CNS Drugs 2022; 36: 919-931.
PubMed
74. Lim JA, et al. Development of the clinical assessment scale in autoimmune encephalitis. Ann Neurol 2019; 85: 352-358.
PubMed
75. Shojima Y, et al. Clinical Characterization of Definite Autoimmune Limbic Encephalitis: A 30-case series. Intern Med 2019; 58: 3369-3378.
PubMed
76. Arino H, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016; 87: 759-765.
PubMed
77. Arino H, et al. Neuroimmune disorders in COVID-19. J Neurol 2022; 269: 2827-2839.
PubMed
78. Kremer S, et al. Neurologic and neuroimaging findings in patients with COVID-19: A retro-spective multicenter study. Neurology 2020; 95: e1868-e1882.
 
79. 小野大介, ほか. -COVID-19神経合併症(1)-脳炎と脳症update. Brain Nerve 2022; 74: 845-851.
 
80. Soung AL, et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain 2022; awac270.
PubMed
81. Vogrig A, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 2020; 91: 772-778.
PubMed
82. Velasco R, et al. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. JAMA Neurol 2021; 78: 864-873.
PubMed
72b. Rodriguez A, et al. LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry. 2022 Mar; 93(3): 309-315. doi: 10. 1136/jnnp-2021-327302.
 
72c. Thompson J, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018; 141: 348-56.
 
P.114 掲載の参考文献
1. Saida T, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005; 64: 621-630.
PubMed
2. Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
PubMed
3. Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
 
4. Takahashi T, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235-1243.
 
5. Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
PubMed
6. Sato DK, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-481.
PubMed
7. Misu T, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005; 65: 1479-1482.
PubMed
8. Kanbayashi T, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009; 66: 1563-1566.
PubMed
9. Banwell B, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22: 268-282.
PubMed
10. Suzuki N, et al. Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010; 74: 1543-1545.
PubMed
11. Chihara N, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108: 3701-3706.
PubMed
12. Pittock SJ, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disor-der. N Engl J Med 2019; 381: 614-625.
 
13. Yamamura T, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2019; 381: 2114-2124.
PubMed
14. Cree BAC, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394: 1352-1363.
PubMed
15. Tahara M, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19: 298-306.
 
P.126 掲載の参考文献
1. Marignier R, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021; 20: 762-772.
PubMed
2. Mader S, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184.
PubMed
3. Ogawa R, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 2017; 4: e322.
PubMed
4. Sato DK, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-481.
PubMed
5. Cobo-Calvo A, et al. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol 2021; 89: 30-41.
PubMed
6. Lopez-Chiriboga AS, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol 2018; 75: 1355-1363.
PubMed
7. Fujimori J, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with an-ti-MOG antibodies. J Neurol Neurosurg Psychiatry 2017; 88: 534-536.
 
8. Matsumoto Y, et al. Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases. J Neurol Neurosurg Psychiatry 2020.
PubMed
9. Waters PJ, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology 2019; 92: e1250-e1255.
PubMed
10. Reindl M, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020; 7: e674.
PubMed
11. Akaishi T, et al. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology 2021; 97: e1-e12.
PubMed
12. Kwon YN, et al. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability. Neurol Neuroimmunol Neuroinflamm 2022; 9.
PubMed
13. Sechi E, et al. Variability of cerebrospinal fluid findings by attack phenotype in myelin oligo-dendrocyte glycoprotein-IgG-associated disorder. Mult Scler Relat Disord 2021; 47: 102638.
 
14. Jarius S, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycopro-tein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 2020; 17: 261.
 
15. Jurynczyk M, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry 2017; 88: 132-136.
 
16. Carandini T, et al. Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Mult Scler Relat Disord 2021; 54: 103118.
PubMed
17. Sechi E, et al. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurol 2021; 78: 741-746.
PubMed
18. Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogen-esis of demyelination. Ann Neurol 2000; 47: 707-717.
 
19. Lassmann H, et al. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121.
PubMed
20. Lassmann H, et al. Experimental allergic encephalomyelitis: the balance between encephalito-genic T lymphocytes and demyelinating antibodies determines size and structure of demyelin-ated lesions. Acta Neuropathol 1988; 75: 566-576.
 
21. Storch MK, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8: 681-694.
PubMed
22. Sakuma H, et al. Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW. 1AV1 rats. Brain 2004; 127: 2201-2213.
PubMed
23. Ogawa R, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 2017; 4: e322.
PubMed
24. Bradl M, et al. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol 2018; 31: 325-333.
PubMed
25. Takai Y, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immuno-pathological study. Brain 2020; 143: 1431-1446.
 
26. Ikeda T, et al. The pathological features of MOG antibody-positive cerebral cortical encephali-tis as a new spectrum associated with MOG antibodies: A case report. J Neurol Sci 2018; 392: 113-115.
 
27. Hoftberger R, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 2020; 139: 875-892.
PubMed
28. Pittock SJ, et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 2007; 13: 7-16.
PubMed
29. O'Connor KC, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13: 211-217.
PubMed
30. Bradl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-643.
PubMed
31. Saadoun S, et al. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014; 2: 35.
PubMed
32. Chihara N, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108: 3701-3706.
PubMed
33. Winklmeier S, et al. Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm 2019; 6: 625.
 
34. Whittam DH, et al. Treatment of MOG-IgG-associated disorder with rituximab: An interna-tional study of 121 patients. Mult Scler Relat Disord 2020; 44: 102251.
 
35. Wang M, et al. Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders. Mult Scler Relat Disord 2021; 53: 103035.
PubMed
36. Tahara M, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neu-rol 2020; 19: 298-306.
 
37. Durozard P, et al. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. Annals of Neurology 2020; 87: 256-266.
PubMed
38. Nepal G, et al. Safety and efficacy of rituximab for relapse prevention in myelin oligodendro-cyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A system-atic review and meta-analysis. J Neuroimmunol 2022; 364: 577812.
 
39. Chen JJ, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020; 95: e111-e120.
PubMed
40. Redenbaugh V, et al. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics 2022; 19: 808-822.
 
41. Elsbernd PM, et al. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associ-ated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord 2021; 48: 102696.
 
P.140 掲載の参考文献
1. Liguori R, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124: 2417-2426.
 
2. Buckley C, et al. Potassium channel antibodies in two patients with reversible limbic encepha-litis. Ann Neurol 2001; 50: 73-78.
 
3. Vincent A, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712.
PubMed
4. Lai M, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785.
PubMed
5. Irani SR, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748.
 
6. Huda S, et al. An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. J Neurol 2015; 262: 418-424.
PubMed
7. Lancaster E, et al. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77: 179-189.
PubMed
8. Uy CE, et al. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol 2021; 21: 412-423.
PubMed
9. Walusinski O, et al. Augustin Morvan (1819-1897), a little-known rural physician and neurol-ogist. Rev Neurol (Paris) 2013; 169: 2-8.
 
10. Irani SR, et al. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241-255.
PubMed
11. Butler CR, et al. Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex. J Neurol Neurosurg Psychiatry 2014; 85: 387-391.
 
12. Malter MP, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephali-tis. Ann Neurol 2010; 67: 470-478.
 
13. Irani SR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900.
PubMed
14. Malter MP, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephali-tis. Ann Neurol 2010; 67: 470-478.
 
15. Naasan G, et al. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 2014; 71: 1300-1304.
PubMed
16. Willis MD, et al. VGKC-complex antibody encephalitis. QJM 2014; 107: 657-659.
PubMed
17. Wieser S, et al. Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disord 2005; 7: 205-211.
PubMed
18. Rocamora R, et al. Pilomotor seizures: an autonomic semiology of limbic encephalitis? Seizure 2014; 23: 670-673.
PubMed
19. Vincent A, et al. Association of Leucine-rich glioma inactivated protein 1, contactin-associated protein 2, and contactin 2 antibodies with clinical features and patient-reported pain in acquired neuromyotonia. JAMA Neurol 2018; 75: 1519-1527.
PubMed
20. Gadoth A, et al. Expanded phenotypes and outcomes among 256LGI1/CASPR2-IgG-positive patients. ANN Neurol 2017; 82: 79-92.
PubMed
21. Boesebeck F, et al. Faciobrachial dystonic seizures arise from corticosubcortical abnormal brain areas. J Neurol 2013; 260: 1684-1686.
 
22. Khan NL, et al. Histopathology of VGKC antibody-associated limbic encephalitis. Neurology 2009; 72: 1703-1705.
PubMed
23. Miller TD, et al. Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain 2017; 140: 1212-1219.
PubMed
24. Kim TJ, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. ANN Neurol 2017; 81: 183-192.
PubMed
25. Binks SNM, al. LGI1, CASPR2 and related antibodies: a molecular evolution of the pheno-types. J Neurol Neurosurg Psychiatry 2018; 89: 526-534.
 
26. Ohkawa T, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Nuerosci 2013; 33: 18161-18174.
PubMed
27. Xu M, et al. Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. J Neurol Neurosurg Psychiatry 2020; 91:177-188.
PubMed
28. Dawes JM, et al. Immune or genetic-mediated disruption of CASPR2 causes pain hypersensi-tivity due to enhanced primary afferent excitability. Neuron 2018; 97: 806-822.
 
29. Irani SR, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013; 136: 3151-3162.
 
30. Irani SR, et al. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 2014; 76: 168-184.
PubMed
31. Sekiguchi Y, et al. Potassium channel antibody-associated encephalitis with hypothalamic lesions and intestinal pseudo-obstruction. J Neurol Sci 2008; 269: 176-179.
PubMed
32. Takahashi H, et al. Development of Isaacs' syndrome following complete recovery of volt-age-gated potassium channel antibody-associated limbic encephalitis. J Neurol Sci 2008; 275: 185-187.
 
P.147 掲載の参考文献
1. Yedla M, et al. Edwin Bickerstaff (1920-2008). J Neurol 2017; 264: 619-620.
PubMed
2. Bickerstaff ER, et al. Mesencephalitis and rhombencephalitis. Br Med J 1951; 2: 77-81.
PubMed
3. Bickerstaff ER. Brain-stem encephalitis: Further observations on a grave syndrome with benign prognosis. Br Med J 1957; 1: 1384-1387.
PubMed
4. Koga M, et al. Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry 2012; 83: 1210-1215.
PubMed
5. 古賀道明. Bickerstaff脳幹脳炎. 免疫性神経疾患 (第2版). 日本臨牀増刊号 2022; 80: 324-327.
 
6. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57-65.
PubMed
7. Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009; 215: 1-9.
PubMed
8. Al-Din AN, et al. Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. Brain 1982; 105: 481-495.
 
9. Ropper AH, et al. Proposed mechanism of ataxia in Fisher's syndrome. Arch Neurol 1983; 40: 537-538.
PubMed
10. Ropper A. Absence of CNS lesion in autopsied patients with Miller-Fisher syndrome. Arch Neurol 1985; 42: 15.
 
11. Ropper AH, et al. Evoked potentials in Guillain-Barre syndrome. Neurology 1986; 36: 587-590.
PubMed
12. Ropper AH. Three patients with Fisher's syndrome and normal MRI. Neurology 1988; 38: 1630-1631.
PubMed
13. Yuki N, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993; 118: 83-87.
 
14. Odaka M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a sub-group associated with Guillain-Barre syndrome. Brain 2003; 126: 2279-2290.
 
15. Ito M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008; 255: 674-682.
 
16. Yoshikawa K, et al. Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody. Neurol Neuroimmunol Neuroinflamm 2020; 7: e889.
 
17. Odaka M, et al. Bilateral ballism in a patient with overlapping Fisher's and Guillain-Barre syndromes. J Neurol Neurosurg Psychiatry 1999; 67: 206-208.
 
18. Kimura M, et al. Abnormal movements in Bickerstaff brainstem encephalitis mimicking anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2021; 78: 1149.
 
19. Zeiner PS, et al. Area postrema syndrome as frequent feature of Bickerstaff brainstem enceph-alitis. Ann Clin Transl Neurol 2018; 5: 1534-1542.
 
20. Ogawara K, et al. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve 2002; 26: 845-849.
 
21. Yoshimura H, et al. Electroencephalographic findings in Bickerstaff's brainstem encephalitis: A possible reflection of the dysfunction of the ascending reticular activating system. Clin Neurophysiol Pract 2020; 6: 29-35.
 
22. Wakerley BR, et al. Atypical Bickerstaff brainstem encephalitis: ataxic hypersomnolence without ophthalmoplegia. J Neurol Neurosurg Psychiatry 2013; 84: 1206-1207.
PubMed
23. Koga M. Experimental approach in research of Guillain-Barre syndrome: A range of patho-geneses mediated by molecular mimicry. Clin Exp Neuroimmunol 2018; 9: 93-100.
 
24. Kimoto K, et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-asso-ciated neuropathies. Neurology 2006; 67: 1837-1843.
 
25. Saito K, et al. Blood-brain barrier destruction determines Fisher/Bickerstaff clinical pheno-types: an in vitro study. J Neurol Neurosurg Psychiatry 2013; 84: 756-765.
 
26. Overell JR, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and relat-ed disorders. Cochrane Database Syst Rev 2007; 2007: CD004761.
 
P.158 掲載の参考文献
1. Brain L, et al. Hashimoto's disease and encephalopathy. Lancet 1966; 2: 512-514.
PubMed
2. Shaw PJ, et al. Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers - report of 5 cases. Neurology 1991; 41: 228-233.
PubMed
3. Ghika-Schmid F, et al. Hashimoto's myoclonic encephalopathy: an underdiagnosed treatable condition? Mov Disord 1996; 11: 555-562.
 
4. Fujii A, et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnos-tic marker of Hashimoto's encephalopathy. J Neuroimmunol 2005; 162: 130-136.
 
5. Yoneda M, et al. High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathy. J Neuroimmunol 2007; 185: 195-200.
 
6. Yoneda M, et al. Hashimoto's encephalopathy. In: Kusunoki S (ed). Neuroimmunological Diseases: Springer; 2016. p235-244.
 
7. Ishitobi M, et al. Hashimoto's encephalopathy with hippocampus involvement detected by continuous arterial spin labeling. Psychiatry Clin Neurosci 2013; 67: 128-129.
PubMed
8. Kishitani T, et al. Limbic encephalitis associated with anti-NH2-terminal of α-enolase antibodies: A clinical subtype of Hashimoto's encephalopathy. Medicine (Baltimore) 2017; 96: e6181.
 
9. Nakagawa H, et al. Hashimoto's encephalopathy presenting with progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry 2007; 78: 196-197.
PubMed
10. Matsunaga A, et al. Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Eur Neurol 2012; 69: 14-20.
PubMed
11. Cossu G, et al. Creutzfeldt-Jakob disease associated with high titer of antithyroid autoantibod-ies: case report and literature review. Neurol Sci 2003; 24: 138-140.
 
12. 村松倫子, ほか. Periodic synchronous dischargeを呈しCreutzfeldt-Jakob病との鑑別を要した橋本脳症の1例. 臨神経 2013; 53: 716-720.
 
13. 甲状腺機能低下症による認知機能低下症の特徴は何か. In:日本神経学会, 監修. 認知症疾患診療ガイドライン2017: 医学書院; 2017. p342-343.
 
14. Wang J, et al. Cognitive impairments in Hashimoto's encephalopathy: a case-control study. PLoS One 2013; 8: e55758.
 
15. Nanri K, et al. Prevalence of autoantibodies and the efficacy of immunotherapy for autoim-mune cerebellar ataxia. Intern Med 2016; 55: 449-454.
 
16. Matsunaga A, et al. Serial brain MRI changes related to autoimmune pathophysiology in Hashimoto encephalopathy with anti-NAE antibodies: A case-series study. J Neurol Sci 2019; 406: 116453.
 
17. Muramatsu T, et al. Pathophysiological decrease in the regional cerebral blood flow in Hashimoto's encephalopathy: a multiple-case SPECT study. Eur Neurol 2014; 72: 13-19.
PubMed
18. Nolte KW, et al. Hashimoto encephalopathy: a brainstem vasculitis? Neurology 2000; 54: 769-770.
PubMed
19. Mattozzi S, et al. Hashimoto encephalopathy in the 21st century. Neurology 2020; 94: e217-e224.
PubMed
20. Yoneda M, et al. Reader response: Hashimoto encephalopathy in the 21st century. https://n.neurology.org/content/reader-response-hashimoto-encephalopathy-21st-century-0
 
21. Diaz-Ramos A, et al. α-Enolase, a multifunctional protein: its role on pathophysiological situ-ations. J Biomed Biotechnol 2012; 2012: 156795.
 
22. Montagna G, et al. Hashimoto's encephalopathy: A rare proteiform disorder. Autoimmun Rev 2016; 15: 466-476.
PubMed
23. Endres D, et al. Plasmapheresis responsive rapid onset dementia with predominantly frontal dysfunction in the context of Hashimoto's encephalopathy. Front Psychiatry 2017; 8: 212.
PubMed
24. Jacob S, et al. Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry 2005; 76: 455-456.
PubMed
25. 米田 誠, ほか. Wes (TM) を用いた自動ウエスタンブロットによる橋本脳症の診断バイオマーカー (抗NAE抗体) の測定系開発. 医学と薬学 2021; 78: 969-976.
Medical*Online
26. Kikuchi A, et al. High prevalence of serum anti-NH2-terminal of α-enolase antibodies in patients with multiple system atrophy and corticobasal syndrome. J Neurol 2021; 268: 4291-4295.
 
27. Novak P, et al. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012; 12: 131.
PubMed
28. Zeniya S, et al. Spinocerebellar ataxia type 31 exacerbated by anti-amino terminal of al-pha-enolase autoantibodies. Intern Med 2022; 61: 2793-2796.
 
P.166 掲載の参考文献
1. Fang B, et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningo-encephalomyelitis. JAMA Neurol 2016; 73: 1297-1307.
 
2. Flanagan EP, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoim-mune astrocytopathy: Analysis of 102 patients. Ann Neurol 2017; 81: 298-309.
 
3. Dubey D, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018; 83: 166-177.
 
4. Long Y, et al. Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study. Eur J Neurol 2018; 25: 477-483.
PubMed
5. Iorio R, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmu-nity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 2018; 89: 138-146.
 
6. Dubey D, et al. Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year. J Neuroimmunol 2018; 321: 157-163.
PubMed
7. Kimura A, et al. Clinical characteristics of autoimmune GFAP astrocytopathy. J Neuroimmu-nol 2019; 332: 91-98.
 
8. Gravier-Dumonceau A, et al. Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study. Neurology 2022; 98: e653-e668.
PubMed
9. Kunchok A, et al. Autoimmune glial fibrillary acidic protein astrocytopathy. Curr Opin Neurol 2019; 32: 452-458.
PubMed
10. Kimura A, et al. Characteristics of Movement Disorders in Patients with Autoimmune GFAP Astrocytopathy. Brain Sci 2022; 12: 462.
PubMed
11. Nakamura S, et al. Self-remitting Elevation of Adenosine Deaminase Levels in the Cerebrospi-nal Fluid with Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Case Report and Review of the Literature. Intern Med 2021; 60: 3031-3036.
 
12. Imanaka S, et al. Autoimmune glial fibrillary acidic protein astrocytopathy with delayed abnormal magnetic resonance imaging findings. eNeurologicalSci 2022; 27: 100403.
PubMed
13. Natori T, et al. Repeated Brain Magnetic Resonance Imaging Provides Clues for the Diagnosis of Autoimmune Glial Fibrillary Acid Protein Astrocytopathy. Intern Med 2022; 61: 2947-2950.
PubMed
14. Sechi E, et al. Glial fibrillary acidic protein IgG related myelitis: characterisation and compari-son with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry 2019; 90: 488-490.
 
15. Shu Y, et al. Brain Immunohistopathology in a Patient with Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. Neuroimmunomodulation 2018; 25: 1-6.
 
16. Tokimura R, et al. Abnormal evoked potentials in autoimmune glial fibrillary acidic protein astrocytopathy. eNeurologicalSci 2020; 18: 100229.
PubMed
17. Rosales JJ, et al. [18F]-FDG PET imaging in autoimmune GFAP meningoencephalomyelitis. Eur J Nucl Med Mol Imaging 2021; 48: 947-948.
PubMed
18. Osakada Y, et al. A case of autoimmune GFAP astrocytopathy with profound weight loss and increased uptake in the spinal cord on 18F-FDG PET. Neurol Clin Neurosci 2021; 9: 95-97.
 
19. Yuan Z, et al. CD8(+) T-cell predominance in autoimmune glial fibrillary acidic protein astrocytopathy. Eur J Neurol 2021; 28: 2121-2125.
PubMed
20. Yamakawa M, et al. Autopsy Case of Meningoencephalomyelitis Associated With Glial Fibrillary Acidic Protein Antibody. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1081.
PubMed
21. Shan F, et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Review of the Literature. Front Immunol 2018; 9: 2802.
PubMed
22. Kimura A, et al. Autoimmune glial fibrillary acidic protein astrocytopathy resembling isolated central nervous system lymphomatoid granulomatosis. J Neuroimmunol 2021; 361: 577748.
PubMed
23. Sasaki K, et al. Relapsing-remitting central nervous system autoimmunity mediated by GFAP-specific CD8 T cells. J Immunol 2014; 192: 3029-3042.
PubMed
24. Kimura A, et al. Cytokines and biological markers in autoimmune GFAP astrocytopathy: The potential role for pathogenesis and therapeutic implications. J Neuroimmunol 2019; 15; 334.
 
25. Martin AL, et al. Ovarian Teratoma Associated with Coexisting Anti-N-Methyl-D-Aspartate Receptor and Glial Fibrillary Acidic Protein Autoimmune Meningoencephalitis in an Adoles-cent Girl: A Case Report. J Pediatr Adolesc Gynecol 2018; 31: 321-324.
 
26. Li J, et al. Autoimmune GFAP astrocytopathy aTher viral encephalitis: A case report. Mult Scler Relat Disord 2018; 21: 84-87.
 
27. Asan L, et al. Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclo-nus aTher COVID-19: a case report. Ther Adv Neurol Disord 2021; 14: 17562864211062824.
 
28. Luessi F, et al. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm 2018; 5: e481.
 
29. Kapadia RK, et al. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoen-cephalitis in a patient receiving nivolumab. J Neuroimmunol 2020; 344: 577259.
 
30. Yang X, et al. Treatment of autoimmune glial fibrillary acidic protein astrocytopathy: Fol-low-up in 7 cases. Neuroimmunomodulation 2017; 24: 113-119.
 
31. Wickel J, et al. Encephalitis with radial perivascular emphasis: Not necessarily associated with GFAP antibodies. Neurol Neuroimmunol Neuroinflamm 2020; 7: e670.
PubMed
32. Shoemaker EI, et al. Primary angiitis of the central nervous system: unusual MR appearance. AJNR Am J Neuroradiol 1994; 15: 331-334.
PubMed
33. Williams DW III, et al. Neurosarcoidosis: gadolinium-enhanced MR imaging. J Comput Assist Tomogr 1990 ;14: 704-707.
 
34. Tateishi U, et al. MR imaging of the brain in lymphomatoid granulomatosis. AJNR Am J Neuroradiol 2001; 22: 1283-1290.
PubMed
35. Ganta K, et al. Radial contrast enhancement on brain magnetic resonance imaging diagnostic of primary angiitis of the central nervous system: a case report and review of the literature. J Med Case Rep 2014; 8: 26.
PubMed
36. Hassan AS, et al. Linear magnetic resonance enhancement and optic neuropathy in primary angiitis of the central nervous system. J Neuroophthalmol 2003; 23: 127-131.
PubMed
37. Yin HX, et al. A Case Report of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Diagnosed ATher Long Term Diagnosis of Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids. Front Neurol 2020; 11: 598650.
 
P.178 掲載の参考文献
1. Sabater L, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: A case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014; 13: 575-586.
 
2. Gaig C, et al. The Sleep Disorder in Anti-IgLON5 Disease. Curr Neurol Neurosci Rep 2018; 18: 41.
PubMed
3. Honorat JA, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 2017; 4: e385.
PubMed
4. Fuseya K, et al. Corticobasal Syndrome in a Patient with Anti-IgLON5 Antibodies. Mov Disord Clin Pract 2020; 7: 557-559.
 
5. Werner J, et al. Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome. Neurol Neuroimmunol Neuroinflamm 2021; 8: e962.
PubMed
6. Hogl B, et al. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet 2015; 385: 1590.
PubMed
7. Bruggemann N, et al. Dystonia, lower limb stiffiness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord 2016; 31: 762-764.
 
8. Gonzalez-Avila C, et al. Altered ioflupane single-photon emission computed tomography in anti-IgLON5 disease: A new case mimicking probable progressive supranuclear palsy and review of the literature. Eur J Neurol 2021; 28: 1392-1395.
PubMed
9. Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496-503.
PubMed
10. Haitao R, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol 2016; 300: 9-10.
PubMed
11. Wenninger S. Expanding the clinical spectrum of IgLON5-syndrome. J Neuromuscul Dis 2017; 4: 337-339.
PubMed
12. Asioli GM, et al. Persistence of Facio-Skeletal Myorhythmia During Sleep in anti-IgLON5 Disease. Mov Disord Clin Pract 2021; 8: 460-463.
PubMed
13. Gaig C, et al. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology 2021; 97: e1367-1381.
PubMed
14. Schroder JB, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuro-immunol Neuroinflamm 2016; 4: e302.
PubMed
15. de Carvalho M, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119: 497-503.
PubMed
16. Strippel C, et al. Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series. Neurol Neuroimmunol Neuroinflamm 2022; 9: e1137.
PubMed
17. Pi Y, et al. Anti-IgLON5 disease with distinctive brain MRI findings responding to immuno-therapy: A case report. Medicine (Baltimore) 2021; 100: e24384.
 
18. Chen H, et al. Distinctive Magnetic Resonance Imaging Findings in IgLON5 Antibody Disease. JAMA Neurol 2020; 77: 125-126.
PubMed
19. Zhang W, et al. Serial 18F-FDG PET/CT Findings in a Patient with IgLON5 Encephalopathy. Clin Nucl Med 2016; 41: 787-788.
 
20. Gaig C, et al. The Sleep Disorder in Anti-IgLON5 Disease. Curr Neurol Neurosci Rep 2018; 18: 41.
PubMed
21. Gaig C, et al. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm 2019; 6: e605.
PubMed
22. Ni Y, et al. Expanding the clinical spectrum of anti-IgLON5 disease: A multicenter retrospec-tive study. Eur J Neurol. 2022; 29: 267-276.
 
23. Gelpi E, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016; 132: 531-543.
PubMed
24. Cagnin A, et al. Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopa-thy. J Alzheimer's Dis 2017; 59: 13-20.
 
25. Hongo Y, et al. An autopsy case of MM2-thalamic subtype of sporadic Creutzfeldt-Jakob disease with Lewy bodies presenting as a sleep disorder mimicking anti-IgLON5 disease. J Neurol Sci 2019; 404: 36-39.
 
26. Karagogeos D. Neural GPI-anchored cell adhesion molecules. Front Biosci 2003; 8: s1304-1320.
PubMed
27. Sabater L, et al. Cellular investigations with human antibodies associated with the anti-Ig-LON5 syndrome. J Neuroinflammation 2016; 13: 226.
 
28. Landa J, et al. Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. Ann Neurol 2020; 88: 1023-1027.
PubMed
29. Ryding M, et al. Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons. Cells 2021; 10: 837.
PubMed
30. Schenck CH, et al. Parasomnia Overlap Disorder: RBD and NREM Parasomnias. In: Schenck CH, et al (eds). Rapid-Eye-Movement Sleep Behavior Disorder: Springer; 2019. p359-369.
 
31. Mangesius S, et al. IgLON5 autoimmunity tested negative in patients with progressive supra-nuclear palsy and corticobasal syndrome. Parkinsonism Relat Disord 2017; 38: 102-103.
 
32. Hasselbacher K, et al. IgLON5 antibodies are infrequent in patients with isolated sleep apnea. Eur J Neurol 2018; 25: e46-e47.
PubMed
33. Bonello M, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol NeuroInflammation 2017; 4: e383.
 
34. Shambrook P, et al. Delayed Benefit from Aggressive Immunotherapy in Waxing and Waning Anti-IgLON5 Disease. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1009.
PubMed
35. Cabezudo-Garcia P, et al. Response to immunotherapy in anti-IgLON5 disease: A systematic review. Acta Neurol Scand 2020; 141: 263-270.
PubMed
36. Wang Y, et al. Improvement in mild anti-IgLON5 encephalopathy without immunotherapy: a case report. BMC Neurol 2021; 21: 120.
PubMed
37. Montojo T, et al. Gaze Palsy, Sleep and Gait Disorder, as Well as Tako-Tsubo Syndrome in a Patient with IgLON5 Antibodies. Mov Disord Clin Pract 2016; 4: 441-443.
 
P.185 掲載の参考文献
1. Boronat A, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4. 2 potassium channels. Ann Neurol 2013; 73: 120-128.
PubMed
2. Lin L, et al. DPP6 domains responsible for its localization and function. J Biol Chem 2014; 289: 32153-32165.
PubMed
3. Sun W, et al. DPP6 establishes the A-type K(+) current gradient critical for the regulation of dendritic excitability in CA1 hippocampal neurons. Neuron 2011; 71: 1102-1115.
PubMed
4. Hara M, et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology 2017; 88: 1340-1348.
PubMed
5. Tobin WO, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83: 1797-1803.
PubMed
6. Balint B, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014; 82: 1521-1528.
PubMed
7. Martinez-Hernandez E, et al. Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. JAMA Neurol 2016; 73: 714-720.
PubMed
8. Lin J, et al. Anti-dipeptidyl-peptidase-like protein 6 encephalitis with pure cerebellar ataxia: a case report. BMC Neurol 2022; 22: 242.
PubMed
9. Piepgras J, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology 2015; 85: 890-897.
PubMed
10. Hara M, et al. Practical approach for the diagnosis of disorders associated with antibodies against neuronal surface proteins. Neurol Clin Neurosci 2020; 9: 56-62.
 
11. Mizoguchi T, et al. Novel qEEG Biomarker to Distinguish Anti-NMDAR Encephalitis From Other Types of Autoimmune Encephalitis. Front Immunol 2022; 13: 845272.
PubMed
12. Mbonde AA, et al. DPPX autoimmune encephalitis: A short report on two patients presenting with classic features of this rare but treatable disease. Mult Scler Relat Disord 2021; 52: 102934.
 
13. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
P.193 掲載の参考文献
1. Moersch FP, et al. Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observation in 13 other cases. Proc Staff Meet Mayo Clin 1956; 31: 421-427.
PubMed
2. Solimena M, et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322: 1555-1560.
PubMed
3. Lorish TR, et al. Stiff-man syndrome updated. Mayo Clin Proc 1989; 64: 629-636.
PubMed
4. Brown P, et al. The stiff leg syndrome. J Neurol Neurosurg Psychiatry 1997; 62: 31-37.
PubMed
5. Saiz A, et al. Stiff-leg syndrome: a focal form of stiff-man syndrome. Ann Neurol 1998; 43:400-403.
PubMed
6. Pallis CA, et al. A subacute progressive encephalopathy with mutism, hypokinesia, rigidity, and myoclonus. Q J Med 1957; 26: 349-373.
PubMed
7. Hutchinson M, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71: 1291-1292.
PubMed
8. Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009; 11: 102-110.
PubMed
9. McKeon A, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69: 230-238.
PubMed
10. Martinez-Hernandez E, et al. Clinical and immunologic investigations in patients with stiff-person spectrum disorder. JAMA Neurol 2016; 73: 714-720.
PubMed
11. Graus F, et al. GAD antibodies in neurological disorders-insights and challenges. Nat Rev Neurol 2020; 16: 353-365.
PubMed
12. Rakocevic G, et al. Autoimmune stiff person syndrome and related myelopathies: understand-ing of electrophysiological and immunological processes. Muscle Nerve 2012; 45: 623-634.
 
13. De Camilli P, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoan-tigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993; 178: 2219-2223.
 
14. Alexopoulos H, et al. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology 2013; 81: 1962-1964.
PubMed
15. Hinson SR, et al. Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2018; 5: e438.
PubMed
16. Butler MH, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000; 26: 307-312.
PubMed
17. El-Abassi R, et al. SPS: Understanding the complexity. J Neurol Sci 2019; 404: 137-149.
PubMed
18. Dalmau J, et al. Antibody-mediated encephalitis. N Engl J Med 2018; 378: 840-851.
PubMed
19. Holmoy T, et al. Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin Neurol Neurosurg 2009; 111: 708-712.
PubMed
20. Ishizawa K, et al. Large motor neuron involvement in Stiff-man syndrome: a qualitative and quantitative study. Acta Neuropathol 1999; 97: 63-70.
PubMed
21. Barker RA, et al. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 1998; 65: 633-640.
PubMed
22. Turner MR, et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor. Neurology 2011; 77: 439-443.
PubMed
23. Tsiortou P, et al. GAD antibody-spectrum disorders: progress in clinical phenotypes, immuno-pathogenesis and therapeutic interventions. Ther Adv Neurol Disord 2021; 14: 17562864211003486.
 
24. Dalakas MC, et al. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol 2017; 82: 271-277.
PubMed
25. Nakane S, et al. Successful treatment of stiff person syndrome with sequential use of tacrolim-us. J Neurol Neurosurg Psychiatry 2013; 84: 1177-1180.
 
P.202 掲載の参考文献
1. Muniz-Castrillo S, et al. Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. Cerebellum 2022; 21: 573-591.
PubMed
2. Yoshida K. Cortical Cerebellar Atrophy and Idiopathic Cerebellar Ataxia: Nomenclature and Diagnostic Approach. Brain Nerve 2020; 72: 923-930.
PubMed
3. Garza M, et al. Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia. Front Neurol 2021; 12: 683048.
PubMed
4. Yaguchi H, et al. Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. J Neurol 2014; 261: 224-226.
 
5. Borsche M, et al. Sez6l2-antibody-associated progressive cerebellar ataxia: a differential diagnosis of atypical parkinsonism. J Neurol 2019; 266: 522-524. .
PubMed
6. Landa J, et al. Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurol Neuroimmunol Neuroinflamm 2020; 8: e916.
PubMed
7. Mehdiyeva A, et al. SEZ6L2 Antibody-Associated Cerebellar Ataxia Responsive to Sequential Immunotherapy. Neurol Neuroimmunol Neuroinflamm 2022; 9: e1131.
PubMed
8. Reis Carneiro D, et al. Sez6l2-associated encephalitis in a patient with small-cell lung cancer. Neurol Sci 2022; 43: 6131-6133.
 
9. Miyazaki T, et al. Disturbance of cerebellar synaptic maturation in mutant mice lacking BSRPs, a novel brain-specific receptor-like protein family. FEBS lett 2006; 580: 4057-4064.
PubMed
10. Ishikawa N, et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006; 97: 737-745.
PubMed
11. Lee JS, et al. SEZ6L2 Is an Important Regulator of Drug-Resistant Cells and Tumor Spheroid Cells in Lung Adenocarcinoma. Biomedicines 2020; 8: 500.
PubMed
12. Chen L, et al. SEZ6L2, regulated by USF1, accelerates the growth and metastasis of breast cancer. Exp Cell Res 2022; 417: 113194.
PubMed
13. Luo X, et al. High expression of SEZ6L2 as an independent prognostic Indicator in thyroid carcinoma. Gland Surg 2022; 11: 412-425.
PubMed
14. Yu Z, et al. Novel 16-Genes Signature Scoring System as Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma. Biomedicines 2022; 10: 317.
PubMed
15. Lu J, et al. Transcriptome-based identification of molecular markers related to the develop-ment and prognosis of Colon cancer 2021; 40: 1114-1124.
 
16. An N, et al. SEZ6L2 knockdown impairs tumour growth by promoting caspase-dependent apoptosis in colorectal cancer. J Cell Mol Med 2020; 24: 4223-4232.
PubMed
17. Wang Z, et al. Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangio-carcinoma. Transl Cancer Res 2020; 9: 6768-6779.
 
18. Wang L, et al. Upregulated Seizure-Related 6 Homolog-Like 2 Is a Prognostic Predictor of Hepatocellular Carcinoma. Dis Markers 2020; 2020: 7318703.
PubMed
19. Dufresne J, et al. The plasma peptides of ovarian cancer. Clin Proteomics 2018; 15: 41.
PubMed
20. Wang Q, et al. CpG methylation patterns are associated with gene expression variation in osteosarcoma. Mol Med Rep 2017; 16: 901-907.
PubMed
21. Yaguchi H, et al. Sez6l2 regulates phosphorylation of ADD and neuritogenesis. Biochem Biophys Res Commun 2017; 494: 234-241.
PubMed
22. Yaguchi H, et al. Anti-Sez6l2 antibody detected in a patient with immune-mediated cerebellar ataxia inhibits complex formation of GluR1 and Sez6l2. J Neurol 2018; 265: 962-965.
 
23. Mitoma H. Immune-Mediated Cerebellar Ataxias. Brain Nerve 2021; 73: 611-619.
PubMed
24. Nash A, et al. Lack of Sez6 Family Proteins Impairs Motor Functions, Short-Term Memory, and Cognitive Flexibility and Alters Dendritic Spine Properties. Cereb Cortex 2020; 30: 2167-2184.
PubMed
25. Qiu WQ, et al. The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases. Front Immunol 2021; 12: 607641.
PubMed
P.212 掲載の参考文献
1. van de Warrenburg BP, et al. Paraneoplastic cerebellar ataxia due to burnt-out testicular germ cell tumour? Eur Neurol 2007; 57: 178-181.
PubMed
2. Ishikawa H, et al. Paraneoplastic neurological syndrome due to burned-out testicular tumor showing hot cross-bun sign. Acta neurol Scand 2016; 133: 398-402.
PubMed
3. Freifeld Y, et al. Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome-Not Quite "Burned Out". Front Neurol 2018; 9: 20.
PubMed
4. Mandel-Brehm C, et al. Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneo-plastic Encephalitis. New Engl J Med 2019; 381: 47-54.
 
5. Dubey D, et al. Expanded Clinical Phenotype, Oncological Associations, and Immunopatho-logic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurol 2020; 77: 1420-1429.
 
6. Maudes E, et al. Clinical significance of Kelch-like protein 11 antibodies. Neurol Neuroimmu-nol Neuroinflamm 2020; 7: e666.
 
7. Vogrig A, et al. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain commun 2021; 3: fcab185.
PubMed
8. Kattah JC, et al. Paraneoplastic Progressive Downbeat Nystagmus, Ataxia and Sensorineural Hearing Loss due to the ANTI-Kelch-11 Protein Antibody. J Neuroophthalmol 2021; 41: 261-265.
 
9. Hoche F, et al. The cerebellar cognitive affective/Schmahmann syndrome scale. Brain 2018; 141: 248-270.
PubMed
10. Scutelnic A, et al. Clinical Reasoning: A Dizzy Architect. Neurology 2022; 98: 543-549.
PubMed
11. Devine MF, et al. Ondine's Curse and Trismus in Association With Kelch-like Protein-11 Autoimmunity. JAMA Neurol 2021; 78: 1016-1017.
PubMed
12. Ishikawa H, et al. Long-term MRI changes in a patient with Kelch-like protein 11-associated paraneoplastic neurological syndrome. Eur J Neurol 2021; 28: 4261-4266.
 
13. Majed M, et al. "Hot Cross Bun" Sign in a Patient With Kelch-like Protein 11 Rhombencepha-litis. Mayo Clin Proc 2022; 97: 122-123.
 
14. Madhavan A, et al. Association between paraneoplastic rhombencephalitis and hypertrophic olivary degeneration. J Neurol Neurosurg Psychiatry 2021; 92: 798-800.
PubMed
15. Delgado-Garcia G, et al. New Technique, New Antibody: Phage Display Identifies Kelch-Like Protein-11 Antibodies. Mov Disord Clin Pract 2020; 8: 215-216.
PubMed
16. Jitprapaikulsan J, et al. Paraneoplastic neurological syndrome: an evolving story. Neurooncol Pract 2021; 8: 362-374.
PubMed
17. Fonseca E, et al. Opsoclonus-myoclonus syndrome associated with anti Kelch-like protein-11 antibodies in a young female patient without cancer. J Neuroimmunol 2021; 355: 577570
 
18. Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140.
PubMed
19. Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1014.
PubMed
20. 井上亜希, ほか. 浮動性めまいと両側進行性感音難聴を呈した傍腫瘍性神経症候群の1例. Equilibrium Res 2021;80:41-49.
 
21. Lucchinetti CF, et al. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies 1998: 50: 652-657.
PubMed
22. Dhanoa BS, et al. Update on the Kelch-like (KLHL) gene family. Hum Genomics 2013;7: 13
PubMed
23. Shi X, et al. Kelch-like proteins: Physiological functions and relationships with diseases. Pharmacol Res 2019; 148: 104404.
PubMed
24. Abboud H, et al. Autoimmune encephalitis: proposed best practice recommendations for diag-nosis and acute management. J Neurol Neurosurg Psychiatry 2021; 92: 757-768.
 

III 神経・精神疾患と自己免疫

P.223 掲載の参考文献
1. Dubey D, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018; 83: 166-177.
 
2. Flanagan EP, et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc 2010; 85: 881-897.
PubMed
3. Kelley BJ, et al. Young-onset dementia: demographic and etiologic characteristics of 235 patients. Arch Neurol 2008; 65: 1502-1508.
PubMed
4. Graus F, et al. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019; 16: 535-548.
PubMed
5. Banks SA, et al. Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. Ther Adv Neurol Disord 2021; 14: 1756286421998906.
PubMed
6. Sechi E, et al. Diagnosis and Management of Autoimmune Dementia. Curr Treat Options Neurol 2019; 21: 11.
PubMed
7. Martinez-Hernandez E, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011; 77: 589-593.
PubMed
8. Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
PubMed
9. Ramberger M, et al. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain 2020; 143: 1731-1745.
PubMed
10. Roberts WK, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119: 2042-2051.
PubMed
11. Tanaka M, et al. Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplas-tic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1999; 168: 28-31.
 
12. Zhang T, et al. Brain MRI Characteristics of Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome. AJNR Am J Neuroradiol 2018; 39: 824-829.
PubMed
13. Kinirons P, et al. Paraneoplastic limbic encephalitis (PLE) and chorea associated with CRMP-5 neuronal antibody. Neurology 2003; 61: 1623-1624.
PubMed
14. Dalmau J, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-1844.
PubMed
15. Spatola M, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurolo-gy 2017; 88: 1012-1020.
 
16. Flanagan EP, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoim-mune astrocytopathy: Analysis of 102 patients. Ann Neurol 2017; 81: 298-309.
 
17. Probasco JC, et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol NeuroinThamm 2017; 4: e352.
PubMed
18. Rey C, et al. Striatal hypermetabolism in limbic encephalitis. J Neurol 2012; 259: 1106-1110.
PubMed
19. Kaplan PW, et al. Electroencephalography of autoimmune limbic encephalopathy. J Clin Neurophysiol 2013; 30: 490-504.
PubMed
20. Schmitt SE, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA recep-tor encephalitis. Neurology 2012; 79: 1094-1100.
 
21. Flanagan EP, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol NeuroinThamm 2015; 2: e161.
PubMed
22. Gruter T, et al. Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity. J Neurol 2020; 267: 715-720.
PubMed
23. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
24. McKeon A, et al. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology 2011; 76: 1108-1110.
PubMed
25. Dechelotte B, et al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurol Neuroimmunol NeuroinThamm 2020; 7: e701.
PubMed
26. Ruiz-Garcia R, et al. The Diagnostic Value of Onconeural Antibodies Depends on How They Are Tested. Front Immunol 2020; 11: 1482.
PubMed
27. van Sonderen A, et al. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol 2017; 13: 290-301.
PubMed
28. Evangelopoulos ME, et al. Treatment of neuromyelitis optica and neuromyelitis optica spec-trum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. J Neurol Sci 2017; 372: 92-96.
 
29. Dinoto A, et al. Treatment Options in Refractory Autoimmune Encephalitis. CNS Drugs 2022; 36: 919-931.
PubMed
30. Abboud H, et al. Autoimmune encephalitis: proposed best practice recommendations for diag-nosis and acute management. J Neurol Neurosurg Psychiatry 2021; 92: 757-768.
 
P.236 掲載の参考文献
1. Dalmau J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychia-trists: mechanisms and models. Lancet Neurol 2019; 18: 1045-1057.
 
2. Pollak TA, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 2020; 7: 93-108.
 
3. Dalmau, J et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
PubMed
4. Al-Diwani A, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019; 6: 235-246.
PubMed
5. Senda M, et al. Anti-inThammatory therapy and immunotherapy were partially effective in a patient with anti-N-Methyl-D-Aspartate receptor antibodies and a special subgroup of treatment-resistant schizophrenia. J Clin Psychopharmacol 2016; 36: 92-93.
 
6. Kawai H, et al. Anti-NMDA-receptor antibody in initial diagnosis of mood disorder. Eur Neuropsychopharmacol 2019; 29: 1041-1050.
PubMed
7. Tsutsui K, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012; 12: 37.
PubMed
8. Shibata T, et al. Rituximab was effective for treatment of anti-N-Methyl-d-Aspartate receptor encephalitis in early adolescence in initially suspected dissociative disorder. Clin Neurophar-macol 2021; 44: 99-100.
 
9. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
10. Lejuste F, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol NeuroinThamm 2016; 3: e280.
PubMed
11) Warren N, et al. Refining the psychiatric syndrome of anti-N-methyl-d-aspartate receptor encephalitis. Acta Psychiatr Scand 2018; 138: 401-408.
PubMed
12) Espinola-Nadurille M, et al. Frequency of neuropsychiatric disturbances in anti-NMDA receptor encephalitis. Acta Psychiatr Scand 2018; 138: 483-485.
PubMed
13. Herken J, et al. Red Flags: Clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry 2017; 8: 25.
PubMed
14. Kanazawa T, et al. Genome-wide association study of atypical psychosis. Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 679-686.
PubMed
15. Komagamine T, et al. "Atypical psychoses" and anti-NMDA receptor encephalitis: A review of literature in the mid-twentieth century. Psychiatry Clin Neurosci 2022; 76: 62-63.
PubMed
16. Hinotsu K, et al. The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms. Schizophr Res 2022; 248: 292-299.
PubMed
17. Jezequel J, et al. Cell- and Single Molecule-Based Methods to Detect Anti-N-Methyl-D-Aspar-tate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. Biol Psychiatry 2017; 82: 766-772.
 
18. Ruiz-Garcia R, et al. Limitations of a commercial assay as diagnostic test of autoimmune encephalitis. Front Immunol 2021; 12: 691536.
PubMed
19. Mino S, et al. Inconsistency of antibody testing in a patient with anti-N-methyl-D-aspartate receptor encephalitis. Asian J Psychiatr 2022; 72: 103124.
 
20. Lai M, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434.
PubMed
21. Kreye J, et al. Human cerebrospinal Thuid monoclonal N-methyl-D-aspartate receptor autoan-tibodies are sufficient for encephalitis pathogenesis. Brain 2016; 139: 2641-2652.
 
22. Jezequel J, et al. Dynamic disorganization of synaptic NMDA receptors triggered by autoanti-bodies from psychotic patients. Nat Commun 2017; 8: 1791.
 
23. Castillo-Gomez E, et al. The brain as immunoprecipitator of serum autoantibodies against N-Methyl-D-aspartate receptor subunit NR1. Ann Neurol 2016; 79: 144-151.
PubMed
24. Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165.
PubMed
25. Irani SR, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667.
 
26. Heine J, et al. Imaging of autoimmune encephalitis-relevance for clinical practice and hippocampal function. Neuroscience 2015; 309: 68-83.
PubMed
27. Gillinder L, et al. EEG findings in NMDA encephalitis-A systematic review. Seizure 2019; 65: 20-24.
PubMed
28. Endres D, et al. Intrathecal thyroid autoantibody synthesis in a subgroup of patients with schizophreniform syndromes. J Neuropsychiatry Clin Neurosci 2017; 29: 365-374.
 
29. Ding J, et al. Clinical features of coexisting anti-NMDAR and MOG antibody-associated encephalitis: A systematic review and meta-analysis. Front Neurol 2021; 12: 711376.
PubMed
30. Tao S, et al. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review. Mult Scler Relat Disord 2019; 35: 185-192.
 
31. Tietz AK, et al. Genome-wide association study identifies 2 new loci associated with an-ti-NMDAR encephalitis. Neurol Neuroimmunol NeuroinThamm 2021; 8: e1085.
 
32. Joubert B, et al. Pregnancy outcomes in anti-NMDA receptor encephalitis: Case series. Neurol Neuroimmunol NeuroinThamm 2020; 7: e668.
PubMed
33. Okamoto S, et al. Impairment of early neuronal maturation in anti-NMDA-receptor encepha-litis. Psychopharmacology (Berl) 2022; 239: 525-531.
 
34. Bergink V, et al. Autoimmune encephalitis in postpartum psychosis. Am J Psychiatry 2015; 172: 901-908.
PubMed
35. Armangue T, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encepha-litis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17: 760-772.
 
36. Linnoila J, et al. Mouse model of anti-NMDA receptor post-herpes simplex encephalitis. Neurol Neuroimmunol NeuroinThamm 2018; 6: e529.
PubMed
37. Salovin A, et al. Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection. Neurol Neuroimmunol NeuroinThamm 2018; 5: e458.
PubMed
38. Franke C, et al. High frequency of cerebrospinal Thuid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun 2021; 93: 415-419.
PubMed
39. Nabizadeh F, et al. Autoimmune encephalitis associated with COVID-19: A systematic review. Mult Scler Relat Disord 2022; 62: 103795.
PubMed
40. Huo S, et al. Intravenous immunoglobulins for treatment of severe COVID-19-related acute encephalopathy. J Neurol 2022; 269: 4013-4020.
PubMed
41. Fang Z, et al. Advances in autoimmune epilepsy associated with antibodies, their potential pathogenic molecular mechanisms, and current recommended immunotherapies. Front Immunol 2017; 8: 395.
PubMed
42. Planaguma J, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015; 138: 94-109.
 
43. Kenna HA, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci 2011; 65: 549-560.
PubMed
44. Gresa-Arribas N, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167-177.
PubMed
45. Dalmau J, et al. Clinical experience and laboratory investigations in patients with an-ti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
 
46. Nosadini M, et al. Use and safety of immunotherapeutic management of N-Methyl-D-Aspar-tate Receptor antibody encephalitis: A meta-analysis. JAMA Neurol 2021; 78: 1333-1344.
 
47. Warren N, et al. Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: A systematic review of cases. Brain Stimul 2019; 12: 329-334.
 
48. Menza MA, et al. Benzodiazepines and catatonia: an overview. Biol Psychiatry 1989; 26: 842-846.
PubMed
49. Pollak TA, et al. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med 2014; 44: 2475-2487.
 
50. Hara M, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology 2018; 90: e1386-e1394.
PubMed
51. Yoshimura B, et al. Anti-NMDA receptor antibody positivity and presentations without seizure, involuntary movement, hypoventilation, or tumor: A systematic review of the litera-ture. J Neuropsychiatry Clin Neurosci 2017; 29: 267-274.
PubMed
52. Steiner J, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013; 70: 271-278.
 
53. Guasp M, et al. Clinical, neuroimmunologic, and CSF investigations in first episode psychosis. Neurology 2021; 97: e61-e75.
PubMed
54. Graus F, et al. Autoimmune encephalitis or autoimmune psychosis? Eur Neuropsychopharma-col 2021; 50: 112-114.
 
55. Wang J, et al. Comparisons between psychiatric symptoms of patients with anti-NMDAR encephalitis and new-onset psychiatric patients. Neuropsychobiology 2017; 75: 72-80.
PubMed
56. Pollak TA, et al. Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis. Biol Psychiatry 2021; 90: 9-15.
PubMed
57. Theorell J, et al. Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis. Transl Psychiatry 2021; 11: 566.
PubMed
58. Sakamoto S, et al. Anti-N-Methyl-D-Aspartate receptor encephalitis in psychiatry. Acta Med Okayama 2019; 73: 189-195.
PubMed
P.245 掲載の参考文献
1. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
2. Toledano M, et al. Autoimmune Epilepsy. Semin Neurol 2015; 35: 245-258.
PubMed
3. 松本理器, ほか. てんかんと自己免疫. Brain Nerve 2017; 69: 1115-1124.
 
4. Scheffer IE, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 512-521.
PubMed
5. Fisher RS, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilep-sia 2017; 58: 522-530.
 
6. Toledano M, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014; 82: 1578-1586.
PubMed
7. 神 一敬. 自己免疫性てんかん. 日本臨床 2018; 76: 1002-1007.
Medical*Online
8. Dubey D, et al. Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology. JAMA Neurol 2017; 74: 397-402.
PubMed
9. Dubey D, et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. J Neuroimmunol 2018; 323: 62-72.
PubMed
10. Dubey D, et al. Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specific-ity and applicability. Epilepsia 2019; 60: 367-369.
 
11. de Bruijn MAAM, et al. ACES Study Group. Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. Ann Neurol 2021; 89: 698-710.
 
12. Chang YC, et al. "Obvious" indications for Neural antibody testing in Epilepsy or Seizures: The ONES checklist. Epilepsia 2022; 63: 1658-1670.
PubMed
13. Vincent A, et al. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol 2010; 23: 144-150.
PubMed
14. 中奥由里子, ほか. Faciobrachial dystonic seizureで初発したくすぶり型の抗leucine-rich glioma-inactivated 1 (LGI1) 抗体陽性辺縁系脳炎の1例. 臨神経 2013; 53: 706-711.
 
15. Tuomilehto J, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-depen-dent diabetes mellitus before clinical onset of disease. Lancet 1994; 343: 1383-1385.
 
16. Mata S, et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 2008; 199: 155-159.
PubMed
17. Vulliemoz S, et al. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxy-lase antibodies. J Neurol Neurosurg Psychiatry 2007; 78: 187-189.
 
18. Peltola J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resis-tant epilepsy. Neurology 2000; 55: 46-50.
 
19. 赤石哲也, ほか. 抗glutamic acid decarboxylase抗体に関連した側頭葉てんかん4例の臨床的特徴. 臨神経 2015;55:804-809.
 
20. Steriade C, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia 2020; 61: 1341-1351.
PubMed
21. Rada A, et al. Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data. J Neurol 2021; 268: 1059-1069.
PubMed
22. Dubey D, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 2017; 58: 1181-1189.
PubMed
23. 急性症候性発作の定義はなにか. In: 日本神経学会 (監). てんかん診療ガイドライン2018: 医学書院; 2018. p153.
 
24. てんかんとはなにか. In: 日本神経学会 (監). てんかん診療ガイドライン2018: 医学書院; 2018. p2-3.
 
P.255 掲載の参考文献
1. Hadjivassiliou M. Immune-mediated acquired ataxias. Handb Clin Neurol 2012; 103: 189-199.
PubMed
2. Muniz-Castrillo S, et al. Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. Cerebellum 2022; 21: 573-591.
PubMed
3. Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol NeuroinThamm 2021; 8: e1014.
PubMed
4. Joubert B, et al. Nonparaneoplastic autoimmune cerebellar ataxias. Curr Opin Neurol 2019; 32: 484-492.
PubMed
5. McKeon A, et al. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011; 122: 381-400.
PubMed
6. Dalmau J, et al. Autoimmune Encephalitis and Related Disorders of the Nervous System: Cam-bridge University Press; 2022.
 
7. Ruiz-Garcia R, et al. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol Neuroimmunol NeuroinThamm 2019; 7: e658.
PubMed
8. Zhang L, et al. Imbalance in circulating T lymphocyte subsets contributes to Hu antibody-as-sociated paraneoplastic neurological syndromes. Cell Immunol 2014; 290: 245-250.
 
9. Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140.
PubMed
10. Peterson K, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931-1937.
 
11. Shams'ili S, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibod-ies: analysis of 50 patients. Brain 2003; 126: 1409-1418.
 
12. McKeon A, et al. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: The cerebel-lum and beyond. Arch Neurol 2011; 68: 1282-1289.
 
13. Bernal F, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230-234.
PubMed
14. Graus F, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-1148.
PubMed
15. Nagashima T, et al. Anti-Hu paraneoplastic syndrome presenting with brainstem-cerebellar symptoms and Lambert-Eaton myasthenic syndrome. Neuropathology 2003; 23: 230-238.
PubMed
16. Honnorat J, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychia-try 1996; 61: 270-278.
 
17. Pittock SJ, et al. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53: 580-587.
PubMed
18. Simard C, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol NeuroinThamm 2020; 7: e699.
PubMed
19. Dubey D, et al. Expanded Clinical Phenotype, Oncological Associations, and Immunopatho-logic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurol 2020; 77: 1420-1429.
 
20. Hoftberger R, et al. Update on neurological paraneoplastic syndromes. Curr Opin Oncol 2015; 27: 489-495.
PubMed
21. Psimaras D, et al. Cerebrospinal Thuid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81: 42-45.
PubMed
22. Escudero D, et al. Antibody-associated CNS syndromes without signs of inThammation in the elderly. Neurology 2017; 89: 1471-1475.
PubMed
23. Saiz A, et al. Detection of 14-3-3 brain protein in the cerebrospinal Thuid of patients with paraneoplastic neurological disorders. Ann Neurol 1999; 46: 774-777.
 
24. Madhavan AA, et al. Imaging review of paraneoplastic neurologic syndromes. AJNR Am J Neuroradiol 2020; 41: 2176-2187.
PubMed
25. Choi KD, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77: 525-528.
PubMed
26. Rojas I, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55: 713-715.
PubMed
27. Titulaer MJ, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18: 19-e13.
 
28. Scaravilli F, et al. The neuropathology of paraneoplastic syndromes. Brain Pathol 1999; 9: 251-260.
PubMed
29. Bernal F, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230-234.
PubMed
30. Uchuya M, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996; 60: 388-392.
PubMed
31. Graus F, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 1992; 42: 536-540.
PubMed
32. Thone J, et al. Effective immunosuppressant therapy with cyclophosphamide and corticoste-roids in paraneoplastic cerebellar degeneration. J Neurol Sci 2008; 272: 171-173.
 
33. Vernino S, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 2004; 6: 55-62.
PubMed
34. Esposito M, et al. Successful treatment of paraneoplastic cerebellar degeneration with Ritux-imab. J Neurooncol 2008; 86: 363-364.
 
P.265 掲載の参考文献
1. Solimena M, et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322: 1555-1560.
PubMed
2. Butler MH, et al. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65. recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993; 178: 2097-2106.
PubMed
3. Graus F, et al. GAD antibodies in neurological disorders - insights and challenges. Nat Rev Neurol 2020; 16: 353-365.
PubMed
4. Manto MU, et al. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis 2011; 6: 3.
PubMed
5. Raju R, et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol 2005; 175: 7755-7762.
PubMed
6. Arino H, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol 2014; 71: 1009-1016.
PubMed
7. Muniz-Castrillo S, et al. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum 2020; 19: 715-721.
 
8. Saiz A, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563.
PubMed
9. Honnorat J, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001; 58: 225-230.
PubMed
10. Arino H, et al. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. JAMA Neurol 2015; 72: 874-881.
PubMed
11. Ishida K, et al. Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxy-lase antibody-associated cerebellar ataxia. J Neurol Neurosurg Psychiatry 2007; 78: 190-192.
 
12. Pin JP, et al. The metabotropic glutamate receptors: structure and functions. Neuropharmacol-ogy 1995; 34: 1-26.
 
13. Coesmans M, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoan-tibodies. Ann Neurol 2003; 53: 325-336.
 
14. Spatola M, et al. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology 2020; 95: e3012-e3025.
PubMed
15. Lopez-Chiriboga AS, et al. Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes. Neurology 2016; 86: 1009-1013.
PubMed
16. Wang J, et al. Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review. J Neuroimmunol 2021; 353: 577515.
PubMed
17. Joubert B, et al. Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associat-ed encephalitis. Neurol Neuroimmunol NeuroinThamm 2017; 4: e371.
 
18. Pittock SJ, et al. GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1. Immunoglobulin-Associated Ataxia and Neuropathy. Mov Disord Clin Pract 2020; 7: 904-909.
PubMed
19. Wenning GK, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple Sys-tem Atrophy. Mov Disord 2022; 37: 1131-1148.
 
20. Shelly S, et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroin-Thamm 2019; 6: e612.
 
21. Alfugham N, et al. ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer associ-ation. Neurol Neuroimmunol NeuroinThamm 2017; 5: e418.
 
22. Liu M, et al. Neurological Autoimmunity Associated With Homer-3 Antibody: A Case Series From China. Neurol Neuroimmunol NeuroinThamm 2021; 8: e1077.
PubMed
23. Yaguchi H, et al. Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. J Neurol 2014; 261: 224-226.
 
24. Borsche M, et al. Sez6l2-antibody-associated progressive cerebellar ataxia: a differential diagnosis of atypical parkinsonism. J Neurol 2019; 266: 522-524.
PubMed
25. Landa J, et al. Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurol Neuroimmunol NeuroinThamm 2020; 8: e916.
PubMed
26. Honorat JA, et al. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. Neurology 2019; 93: e954-e963.
PubMed
27. Landa J, et al. Encephalitis with Autoantibodies against the Glutamate Kainate Receptors GluK2. Ann Neurol 2021; 90: 101-117.
PubMed
28. Honorat JA, et al. Autoimmune septin-5 cerebellar ataxia. Neurol Neuroimmunol Neuroin-Thamm 2018; 5: e474.
 
29. Dalmau J, et al. Autoimmune Encephalitis and Related Disorders of the Nervous System: Cam-bridge University Press; 2022.
 
P.273 掲載の参考文献
1. O'Toole O, et al. Autoimmune chorea in adults. Neurology 2013; 80: 1133-1144.
PubMed
2. Yu Z, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49: 146-154.
PubMed
3. Vernino S, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51: 625-630.
PubMed
4. Gaig C, et al. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology 2021; 97: e1367-e1381.
PubMed
5. Tofaris GK, et al. Immunotherapy-responsive chorea as the presenting feature of LGI1-anti-body encephalitis. Neurology 2012; 79: 195-196.
 
6. Ramdhani RA, et al. Isolated chorea associated with LGI1 antibody. Tremor Other Hyperkinet Mov (N Y). 2014; 4: tre-04-213-4821-1.
 
7. Vynogradova I, et al. Hemichorea Associated with CASPR2 Antibody. Tremor Other Hyperki-net Mov (N Y). 2014; 4: 239.
 
8. Zekeridou A, et al. Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neuro-logic autoimmunity. Neurology 2019; 93: e815-e822.
 
9. Asherson RA, et al. Chorea in systemic lupus erythematosus and "lupus-like" disease: associa-tion with antiphospholipid antibodies. Semin Arthritis Rheum 1987; 16: 253-259.
 
10. Cervera R, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum 2002; 46: 1019-1027.
 
11. Reiner P, et al. Long-term outcome of 32 patients with chorea and systemic lupus erythemato-sus or antiphospholipid antibodies. Mov Disord 2011; 26 :2422-2427.
PubMed
12. Kyle K, et al. Autoimmune and Paraneoplastic Chorea: A Review of the Literature. Front Neurol 2022; 13: 829076.
PubMed
13. Cardoso F, et al. Chorea in fifty consecutive patients with rheumatic fever. Mov Disord 1997; 12: 701-703.
PubMed
14. Duan BC, et al. Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis: A nationwide study in Taiwan. Medicine (Baltimore). 2016; 95: e4365.
 
15. Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
PubMed
16. Armangue T, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encepha-litis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17: 760-772.
 
17. Dale RC, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012; 135: 3453-3468.
PubMed
18. Hara M, et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology 2017; 88: 1340-1348.
PubMed
19. Mohammad SS, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord 2014; 29: 117-122.
PubMed
20. Oh SY, et al. Update on opsoclonus-myoclonus syndrome in adults. J Neurol 2019; 266: 1541-1548.
PubMed
21. Armangue T, et al. Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol 2016; 73: 417-424.
PubMed
22. Bhatia P, et al. Opsoclonus-myoclonus-ataxia syndrome in children. J Neurol 2022; 269: 750-757.
 
23. Kurian M, et al. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol 2010; 67: 118-121.
PubMed
24. Petit-Pedrol M, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13: 276-286.
 
25. Brown P, et al. The stiff man and stiff man plus syndromes. J Neurol 1999; 246: 648-652.
PubMed
26. Martinez-Hernandez E, et al. Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. JAMA Neurol 2016; 73: 714-720.
PubMed
27. Balint B, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014; 82: 1521-1528.
PubMed
28. Tobin WO, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83: 1797-1803.
PubMed
29. Tan KM, et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurolo-gy 2008; 70; 1883-1890.
 
30. Geschwind MD, et al. Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol 2008; 65: 1341-1346.
PubMed
31. Kimura A, et al. Characteristics of Movement Disorders in Patients with Autoimmune GFAP Astrocytopathy. Brain Sci 2022; 12: 462.
PubMed
32. Balint B, et al. Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci 2013; 327: 73-74.
PubMed
33. Govert F, et al. Orthostatic myoclonus associated with Caspr2 antibodies. Neurology 2016; 86: 1353-1355.
PubMed
34. Dalmau J, et al. Clinical experience and laboratory investigations in patients with an-ti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
 
35. Spatola M, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurolo-gy 2017; 88: 1012-1020.
 
36. Gresa-Arribas N, et al. Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology 2016; 86: 2235-2242.
 
37. Pittock SJ, et al. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 2010; 67:1109-1115.
PubMed
38. Xia C, et al. Teaching Video NeuroImages: dystonic posturing in anti-NMDA receptor enceph-alitis. Neurology 2011; 76: e80.
 
39. Rubio-Agusti I, et al. Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord 2011; 26: 351-352.
PubMed
40. Mohammad SS, et al. Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord 2014; 29: 1539-1542.
PubMed
41. Irani SR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900.
PubMed
42. van Sonderen A, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87: 1449-1456.
PubMed
43. Dalmau J, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127:1831-1844.
PubMed
44. Matsumoto L, et al. Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. Mov Disord 2007; 22: 728-731.
PubMed
45. Adams C, et al. Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma. Arch Neurol 2011; 68: 521-524.
PubMed
46. Hoglinger GU, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017; 32: 853-864.
PubMed
47. Gonzalez-Avila C, et al. Altered ioThupane single-photon emission computed tomography in anti-IgLON5 disease: A new case mimicking probable progressive supranuclear palsy and review of the literature. Eur J Neurol 2021; 28: 1392-1395.
PubMed
48. Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496-503.
PubMed
49. Fuseya K, et al. Corticobasal Syndrome in a Patient with Anti-IgLON5 Antibodies. Mov Disord Clin Pract 2020; 7: 557-559.
 
50. Kurtis MM, et al. Immunomodulated parkinsonism as a presenting symptom of LGI1 anti-body encephalitis. Parkinsonism Relat Disord 2015; 21:1286-1287.
 
51. Kannoth S, et al. Autoimmune atypical parkinsonism - A group of treatable parkinsonism. J Neurol Sci 2016; 362: 40-46.
PubMed
52. Hierro XM, et al. Moaning phenomenon and rapidly progressive dementia in anti LGI-1 associated progressive Supranuclear palsy syndrome. Tremor Other Hyperkinet Mov (N Y). 2020; 10: 8.
PubMed
53. Pittock SJ, et al. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53: 580-587.
PubMed
54. Simard C, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol NeuroinThamm 2020; 7: e699.
PubMed
55. Takkar A, et al. Anti- RI antibody associated progressive supranuclear palsy like presentation in a patient with breast carcinoma. J Neuroimmunol 2020; 347: 577345.
 
56. Pittock SJ, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81: 1207-1214.
PubMed
57. Bowen LN, et al. Apraxia in anti-glutamic acid decarboxylase-associated stiff person syn-drome: link to corticobasal degeneration? Ann Neurol 2015; 77: 173-176.
 
58. Coban A, et al. Evaluation of incidence and clinical features of antibody-associated autoim-mune encephalitis mimicking dementia. Behav Neurol 2014; 2014: 935379.
 
59. Tada S, et al. Severe parkinsonism associated with anti-CRMP5 antibody-positive paraneo-plastic neurological syndrome and abnormal signal intensity in the bilateral basal ganglia. J Neurol Neurosurg Psychiatry 2016; 87: 907-910.
 
60. Dash D, et al. Paraneoplastic syndrome mimicking progressive supranuclear palsy. J Clin Neurosci 2016; 32: 162-163.
PubMed
61. Ohyagi M, et al. Subacute Supranuclear Palsy in anti-Hu Paraneoplastic Encephalitis. Can J Neurol Sci 2017; 44: 444-446.
PubMed
62. Ricigliano VAG, et al. MSA Mimic? Rare Occurrence of Anti-Hu Autonomic Failure and Thymoma in a Patient with Parkinsonism: Case Report and Literature Review. Front Neurosci 2018; 12: 17.
 
63. Endres D, et al. Parkinsonian Syndrome with Frontal Lobe Involvement and Anti-Glycine Receptor Antibodies. Brain Sci 2020; 10: 399.
PubMed
64. Piquet AL, et al. Novel clinical features of glycine receptor antibody syndrome: A series of 17 cases. Neurol Neuroimmunol NeuroinThamm 2019; 6: e592.
PubMed
65. Balint B, et al. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain 2018; 141: 13-36.
PubMed
P.286 掲載の参考文献
1. American academy of sleep medicine. International Classification of Sleep Disorders. 3rd ed: American academy of sleep medicine; 2014.
 
2. da Mota Gomes M. Encephalitis lethargica epidemic milestones in early sleep neurobiology researches. Sleep Med 2020; 74: 349-356.
PubMed
3. Provini F, et al. Agrypnia excitata. Curr Neurol Neurosci Rep 2013; 13: 341.
PubMed
4. AlShareef SM, et al. Kleine-Levin syndrome: clues to aetiology. Sleep Breath 2018; 22: 613-623.
PubMed
5. Kanbayashi, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009; 66: 1563-1566.
PubMed
6. Dalmau J, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-1844.
PubMed
7. Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
PubMed
8. Blattner MS, et al. Sleep disturbances are common in patients with autoimmune encephalitis. J Neurol 2019; 266: 1007-1015.
PubMed
9. Sabater L, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014; 13: 575-586.
 
10. Chokroverty S. Overview of sleep & sleep disorders. Indian J Med Res 2010; 131: 126-140.
PubMed
11. 日本睡眠学会 (編) . 改訂版 臨床睡眠検査マニュアル: ライフサイエンス; 2015.
 
12. Littner MR, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005; 28: 113-121.
PubMed
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
PubMed
14. Iorio R, et al. Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders. Handb Clin Neurol 2021; 181: 173-186.
PubMed
15. Munoz-Lopetegi A, et al. Sleep disorders in autoimmune encephalitis. Lancet Neurol 2020; 19: 1010-1022.
 
16. Ancona C, et al. Autoimmune Encephalitis and Other Neurological Syndromes With Rare Neuronal Surface Antibodies in Children: A Systematic Literature Review. Front Pediatr 2022; 10: 866074.
PubMed
17. Devine MF, et al. Sleep Disturbances Associated with Neurological Autoimmunity. Neurother-apeutics 2021; 18: 181-201.
 
18. Al-Diwani A, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019; 6: 235-246.
PubMed
19. Gurrera RJ. Recognizing psychiatric presentations of anti-NMDA receptor encephalitis in chil-dren and adolescents: A synthesis of published reports. Psychiatry Clin Neurosci 2019; 73: 262-268.
 
20. Arino H, et al. Sleep disorders in anti-NMDAR encephalitis. Neurology 2020; 95: e671-e684.
PubMed
21. van Sonderen A, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016; 87: 1449-1456.
PubMed
22. Arino H, et al. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology 2016; 87: 759-765.
PubMed
23. Li W, et al. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study. BMC Neurol 2018; 18: 96.
PubMed
24. Zhu F, et al. Clinical Characteristics of Anti-GABA-B Receptor Encephalitis. Front Neurol 2020; 11: 403.
PubMed
25. Cui J, et al. The gamma-aminobutyric acid-B receptor (GABAB) encephalitis: clinical manifes-tations and response to immunotherapy. Int J Neurosci 2018; 128: 627-633.
 
26. Ronchi NR, et al. Comparison of the clinical syndromes of anti-GABAa versus anti-GABAb associated autoimmune encephalitis: A systematic review. J Neuroimmunol 2022; 363: 577804.
PubMed
27. Irani SR, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241-255.
PubMed
28. Petit-Pedrol M, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13: 276-286.
 
29. Deng B, et al. MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series. Neurol Neuroimmunol NeuroinThamm 2022; 9: e1158.
PubMed
30. Mas N, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011; 82: 1399-1401.
PubMed
31. Schmidt C, et al. Progressive encephalomyelitis with rigidity and myoclonus preceding otherwise asymptomatic Hodgkin's lymphoma. J Neurol Sci 2010; 291: 118-120.
PubMed
32. Yao Q, et al. Inspiratory laryngeal stridor as the main feature of progressive encephalomyelitis with rigidity and myoclonus: a case report and literature review. BMC Neurol 2022; 22: 42.
PubMed
33. Sexauer W, et al. Dyspnea in Patients with Stiff-Person Syndrome. Am J Med Sci 2019; 358: 268-272.
PubMed
34. Lai M, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434.
PubMed
35. Hoftberger R, et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology 2015; 84: 2403-2412.
 
36. Tobin WO, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83: 1797-1803.
PubMed
37. Hara M, et al. DPPX antibody-associated encephalitis Main syndrome and antibody effects. Neurology 2017; 88: 1340-1348.
PubMed
38. Xiao J, et al. Clinical and imaging analysis to evaluate the response of patients with anti-DPPX encephalitis to immunotherapy. BMC Neurol 2022; 22: 129.
PubMed
39. Honorat JA, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol NeuroinThamm 2017; 4: e385.
PubMed
40. Gaig C, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017; 88: 1736-1743.
PubMed
41. Spatola M, et al. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Neurology 2018; 90: e1964-e1972.
PubMed
42. Nozaki H, et al. A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. Sleep Med 2009; 10: 253-255.
PubMed
43. Suzuki K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypo-thalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol 2012; 69: 1355-1359.
 
44. Landolfi JC. Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: case study. Neuro Oncol 2003; 5: 214-216.
 
45. Dauvilliers Y, et al. Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol 2013; 70: 1305-1310.
PubMed
46. Saiz A, et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry 2009; 80: 404-407.
PubMed
47. Pittock SJ, et al. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 2010; 67: 1109-1115.
PubMed
48. Simard C, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol NeuroinThamm 2020; 7: e699.
PubMed
P.298 掲載の参考文献
1. Vernino S, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune auto-nomic neuropathies. N Engl J Med 2000; 343: 847-855.
 
2. 中根俊成, ほか. 免疫系と自律神経系のインターフェース. 日臨免疫会誌 2017; 40: 352-360.
 
3. Vernino S, et al. Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 2009; 146: 3-7.
 
4. Nakane S, et al. A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy. J Autoimmun 2020; 108: 102403.
PubMed
5. Young RR, et al. Pure pan-dysautonomia with recovery. Description and discussion of diag-nostic criteria. Brain 1975; 98: 613-636.
 
6. Dhamija R, et al. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol 2008; 6: 988-992.
PubMed
7. Nakane S, et al. Extra-autonomic manifestations in autoimmune autonomic ganglionopathy: a Japanese survey. J Neurol Neurosurg Psychiatry 2017; 88: 367-368.
PubMed
8. Okada F. Psychiatric aspects of acute pandysautonomia. Eur Arch Psychiatry Clin Neurosci 1990; 240: 134-135.
PubMed
9. Hayashi M, et al. A Japanese case of autoimmune autonomic ganglionopathy (AAG) and a review of AAG cases in Japan. Auton Neurosci 2009; 146: 26-28.
 
10. Kuki I, et al. Autoimmune autonomic ganglionopathy in a pediatric patient presenting with acute encephalitis. Brain Dev 2016; 38: 605-608.
 
11. Yamakawa M, et al. Antibodies to the α3 subunit of the ganglionic-type nicotinic acetylcho-line receptors in patients with autoimmune encephalitis. J Neuroimmunol 2020; 349: 577399.
 
12. 小池春樹, ほか. Autoimmune autonomic ganglionopathyとacute autonomic and sensory neuropathy. 臨神経 2013; 53: 1326-1329.
 
13. Koike H, et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 2010; 133: 2881-2896.
PubMed
14. Mukaino A, et al. Insights from the ganglionic acetylcholine receptor autoantibodies in patients with Sjogren's syndrome. Mod Rheumatol 2016; 26: 708-715.
PubMed
15. Maeda Y, et al. Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis. Mod Rheumatol 2017; 27: 664-668.
PubMed
16. 山川 誠, ほか. 自己免疫性自律神経節障害: 10の課題. 末梢神経 2021; 32: 38-46.
Medical*Online
17. Yamakawa M, et al. gAChR antibodies in children and adolescents with acquired autoimmune dysautonomia in Japan. Ann Clin Transl Neurol 2021; 8: 790-799.
PubMed
18. Sletten DM, et al. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 2012; 87: 1196-1201.
PubMed
19. Adams D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21.
PubMed
20. Kimpinski K, et al. Sudomotor dysfunction in autoimmune autonomic ganglionopathy. Neurology 2009; 73: 1501-1506.
PubMed
21. Goldstein DS, et al. Clinical laboratory evaluation of autoimmune autonomic ganglionopathy: Preliminary observations. Auton Neurosci 2009; 146: 18-21.
PubMed
22. Iodice V, et al. Efficacy of immunotherapy in seropositive and seronegative putative autoim-mune autonomic ganglionopathy. Neurology 2009; 72: 2002-2008.
 
23. Wang Z, et al. Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcho-line receptor current. Neurology 2007; 68: 1917-1921.
 
24. Kobayashi S, et al. Autoantibody-induced internalization of nicotinic acetylcholine receptor α3 subunit exogenously expressed in human embryonic kidney cells. J Neuroimmunol 2013; 257: 102-106.
 
25. Maeda Y, et al. Association between anti-ganglionic nicotinic acetylcholine receptor (gAChR)antibodies and HLA-DRB1 alleles in the Japanese population. PLoS One 2016; 11: e0146048.
PubMed
26. Lennon VA, et al. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003; 111: 907-913.
PubMed
27. Vernino S, et al. Experimental autoimmune autonomic neuropathy. J Neurophysiol 2003; 90: 2053-2059.
PubMed
28. Vernino S, et al. Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci 2004; 24: 7037-7042.
PubMed
29. Xu W, et al. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 1999; 96: 5746-5751.
PubMed
30. Kruse AC, et al. Muscarinic acetylcholine receptors: novel opportunities for drug develop-ment. Nat Rev Drug Discov 2014; 13: 549-560.
 
31. Dineley KT, et al. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 2015; 36: 96-108.
PubMed
32. Iodice V, et al. Immunotherapy for autoimmune autonomic ganglionopathy. Auton Neurosci 2009; 146: 22-25.
PubMed
33. Schroeder C, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med 2005; 353: 1585-1590.
PubMed
34. Winston N, et al. Recent advances in autoimmune autonomic ganglionopathy. Curr Opin Neurol 2010; 23: 514-518.
PubMed
35. Gupta A, et al. Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy. Clin Auton Res 2015; 25: 255-258.
PubMed
36. Bouxin M, et al. Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: Case-report and literature review. J Neuroimmunol 2019; 326: 28-32.
PubMed
37. Hayashi T, et al. Effectiveness of treatment for 31 patients with seropositive autoimmune autonomic ganglionopathy in Japan. Ther Adv Neurol Disord 2022; 15: 17562864221110048.
PubMed
38. Vernino S, et al. Invited Article: Autonomic ganglia: target and novel therapeutic tool. Neurol-ogy 2008; 70: 1926-1932.
 
39. Urriola N, et al. Evaluation of commercially available antibodies and Thuorescent conotoxins for the detection of surface ganglionic acetylcholine receptor on the neuroblastoma cell line, IMR-32 by Thow cytometry. J Immunol Methods 2021; 498: 113124.
 
40. Karagiorgou K, et al. Novel cell-based assay for alpha-3 nicotinic receptor antibodies detects antibodies exclusively in autoimmune autonomic ganglionopathy. Neurol Neuroimmunol NeuroinThamm 2022; 9: e1162.
PubMed
41. Wallukat G, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021; 4: 100100.
PubMed
42. 中根俊成, ほか. アセチルコリン受容体に対する自己抗体と脳炎・脳症. 日内会誌 2017; 106: 1571-1578.
 
P.308 掲載の参考文献
1. Johnson DB, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 2019; 25: 1243-1250.
PubMed
2. Nersesjan V, et al. Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review. Neurology 2021; 97: e191-e202.
PubMed
3. Suzuki S. Encephalitis as an immune-related adverse event. J Neurol Neurosurg Psychiatry 2020; 91: 680.
PubMed
4. Sato K, et al. Neurological and related adverse events in immune checkpoint inhibitors: a phar-macovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 2019; 145: 1-9.
 
5. Vogrig A, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 2020; 91: 772-778.
PubMed
6. Shah S, et al. Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma. Case Rep Neurol Med 2018; 2018: 2548528
PubMed
7. Chang H, et al. HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. Ann Clin Transl Neurol 2020; 7: 2243-2250.
PubMed
8. Vogrig A, et al. Increased frequency of anti-Ma2 encephalitis associated with immune check-point inhibitors. Neurol Neuroimmunol NeuroinThamm 2019; 6: e604.
 
9. Williams TJ, et al. Association of Autoimmune Encephalitis With Combined Immune Check-point Inhibitor Treatment for Metastatic Cancer. JAMA Neurol 2016; 73: 928-933.
 
10. 鈴木重明. 免疫チェックポイント阻害薬に伴う神経系の免疫関連有害事象. 日内会誌 2021; 110: 1611-1616.
 
11. Fujiwara S, et al. Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis. Intern Med 2019; 58: 2871-2874.
PubMed
12. Seki M, et al. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol Immunother 2022; 71: 769-775.
PubMed
13. Shibaki R, et al. Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoanti-body-positive patient. Jpn J Clin Oncol 2019; 49: 793-794.
 
14. Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol NeuroinThamm 2021; 8: e1014.
PubMed
P.316 掲載の参考文献
1. de Bruijn MAAM, et al. Pediatric autoimmune encephalitis: Recognition and diagnosis. Neurol Neuroimmunol NeuroinThamm 2020; 7: e682.
PubMed
2. Cellucci T, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediat-ric patient. Neurol Neuroimmunol NeuroinThamm 2020; 7: e663.
 
3. Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
PubMed
4. Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165.
PubMed
5. Florance NR, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66: 11-18.
 
6. Armangue T, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013; 162: 850-856. e2.
 
7. Nishida H, et al. Evaluation of the diagnostic criteria for anti-NMDA receptor encephalitis in Japanese children. Neurology 2021; 96: e2070-e2077.
PubMed
8. Jordan Cole, et al. Acute disseminated encephalomyelitis in children: An updated review based on current diagnostic criteria. Pediatr Neurol 2019; 100: 26-34.
PubMed
9. Gaspard N, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-relat-ed epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia 2018; 59: 745-752.
 
10. Gaspard N, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology 2015; 85: 1604-1613.
PubMed
11. Sakuma H, et al. Intrathecal overproduction of proinThammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry 2015; 86: 820-822.
PubMed
12. de Bruijn MAAM, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 2019; 92: e2185-e2196.
PubMed
13. Broadley J, et al. Prognosticating autoimmune encephalitis: A systematic review. J Autoimmun 2019; 96: 24-34.
PubMed
14. 飯塚高浩. 自己免疫性脳炎における早期診断と早期治療の重要性. 神経治療 2018; 35: 231-236.
Medical*Online
15. 小俣 卓. 自己抗体介在性脳疾患. 小児内科 2020; 52: 375-380.
Medical*Online
16. Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165.
PubMed
17. Anlar B, et al. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics 2003; 34: 194-199.
PubMed

IV 自己抗体一覧

P.320 掲載の参考文献
1) Jain A, et al. Cellular, synaptic, and circuit effects of antibodies in autoimmune CNS synaptopa-thies. Handb Clin Neurol. 2016; 133: 77-93.
 
2) Balint B, et al. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain. 2018; 141: 13-36.
PubMed
P.321 掲載の参考文献
1) Wirtz PW, et al. HLA and smoking in prediction and prognosis of small cell lung can-cer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2005; 159: 230-237.
 
2) Bekircan-Kurt CE, et al. Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases. 2015; 3: 293-300.
PubMed
3) McKasson M, et al. Voltage-gated calcium channel autoimmune cerebellar degenera-tion: Case and study of cytotoxicity. Neurol Neuroimmunol Neuroinflamm. 2016; 3: e222.
 
4) Kelley BP, et al. Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis. AJNR Am J Neuroradiol. 2017; 38: 1070-1078.
PubMed
P.322 掲載の参考文献
1) Campana IG, et al. Anti-Tr/DNER Antibody-Associated Cerebellar Ataxias: a Sys-temic Review. The Cerebellum 2021. online ahead of print.
 
2) de Graaff E, et al. IdentiThcation of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71(6): 815-824.
PubMed
3) Tohgo A, et al. Impaired cerebellar functions in mutant mice lacking. DNER. Mol Cell Neurosci. 2006; 31(2): 326-333.
PubMed
4) Saito SY, et al. DNER as key molecule for cerebellar maturation. Cerebellum 2006; 5(3): 227-231.
PubMed
P.323 掲載の参考文献
1) Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008; 7: 1091-1098.
PubMed
2) Dalmau J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019 Nov; 18(11): 1045-1057.
PubMed
P.324 掲載の参考文献
1) Arino H, et al. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology. 2016; 87: 759-765.
PubMed
1) Sonderen A, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neu-rology. 2016; 87: 521-528.
 
2) Binks S, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. BRAIN 2018: 141; 2263-2271.
PubMed
2) Binks S, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. BRAIN 2018: 141; 2263-2271.
PubMed
3) Lai M, et al: Investigation of LGI1 as the antigen in limbic encephalitis previously at-tributed to potassium channels: a case series. Lancet Neurol 2010: 9; 776-785.
 
3) Sonderen A, et al. From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time. Autoimmunity Reviews . 2016; 15: 970-974.
PubMed
4) Ohkawa T, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neu-tralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013; 33: 18161-18174.
 
P.325 掲載の参考文献
1) Jarius S, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory fea-tures, treatment responses, and long-term outcome. J Neuroinflammation. 2016; 13:280.
 
2) Marignier R, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021; 20: 762-772.
PubMed
3) Chen JJ, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95:e111-e120.
PubMed
P.326 掲載の参考文献
1) Alvarenga MP, et al. Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis. Sci Rep. 2021; 11: 152.
PubMed
2) Papadopoulos MC, et al. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012; 11: 535-544.
PubMed
3) Levy M, et al. New therapies for neuromyelitis optica spectrum disorder. Lancet Neu-rol. 2021; 20(1): 60-67
 
P.327 掲載の参考文献
1) Spatola M, et al. Clinical features, prognostic factors, and antibody effects in an-ti-mGluR1 encephalitis. Neurology 2020; 95: e3012-e3025.
 
1) Dalmau J, et al. Antibody-Mediated Encephalitis. N Engl J Med. 2018; 378: 840-851.
PubMed
2) Zhang TY, et al. Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review. Front Immunol. 2021; 12: 652820.
PubMed
2) Masanobu K, et al. Type-1 metabotropic glutamate receptor signaling in cerebellar Purkinje cells in health and disease. F1000Res 2017; 6: 416.
 
3) Peng X, et al. Cellular plasticity induced by anti-α-amino-3-hydroxy-5-meth-yl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol. 2015; 77: 381-398.
 
4) Lai M, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009; 65: 424-434.
PubMed
5) Joubert B, et al. Clinical Spectrum of Encephalitis Associated With Antibodies Against the α-Amino-3-Hydroxy-5- Methyl-4-Isoxazolepropionic Acid Receptor Case Series and Review of the Literature. JAMA Neurol. 2015; 72: 1163-1169.
 
P.328 掲載の参考文献
1) Lancaster E, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010; 9: 67-76.
 
2) van Coevorden-Hameete MH, et al. he expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain. 2019; 142: 1631-1643.
 
3) Nibber A, et al. Pathogenic potential of antibodies to the GABA B receptor. Epilepsia Open. 2017; 2: 355-359.
 
4) Hoftberger R, et al. Encephalitis and GABAB receptor antibodies: novel Thndings in a new case series of 20 patients. Neurology. 2013; 81: 1500-1506.
 
P.329 掲載の参考文献
1) Spatola M, et al. Encephalitis with mGluR5 antibodies Symptoms and antibody effects. Neurology. 2018; 90: e1964-e1972.
PubMed
1) Hara M, et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology. 2017; 88: 1340-1348.
PubMed
P.330 掲載の参考文献
1) Gaig C, et al. The Sleep Disorder in Anti-IgLON5 Disease. Curr Neurol Neurosci Rep. Current Neurology and Neuroscience Reports 2018; 18: 1-9.
PubMed
1) Spatola M, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017; 88: 1012-1020.
PubMed
2) Ohkawa T, et al. IdentiThcation and characterization of GABA(A) receptor autoanti-bodies in autoimmune encephalitis. J Neurosci. 2014;34:8151-8163.
 
2) Gaig C, et al. Frequency and Characterization of Movement Disorders in Anti-Ig-LON5 Disease. Neurology. 2021; 97: e1367-e1381.
 
3) Strippel C, et al. Increased Intrathecal B and Plasma Cells in Patients With Anti-Ig-LON5 Disease: A Case Series. Neurol Neuroimmunol Neuroinflamm. 2022; 9: e1137.
 
4) Cabezudo-Garcia P, et al. Response to immunotherapy in anti-IgLON5 disease: A systematic review. Acta Neurol Scand 2020; 141: 263-270.
PubMed
P.332 掲載の参考文献
1) Carvajal-Gonzalez A, et al. Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice. Neuropathol Appl Neurobiol. 2021; 47: 316-327.
PubMed
1) Gresa-Arribas N, et al. Human neurexin-3 α antibodies associate with encephalitis and alter synapse development. Neurology. 2016; 86: 2235-2242.
 
2) Hansen N, et al. Mild Amnestic Cognitive Impairment and Depressive Symptoms in Autoimmune Encephalitis Associated with Serum Anti-Neurexin-3 α Autoantibod-ies. Brain Sci. 2021; 11: 673.
 
2) Crisp SJ, et al. Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain. 2019; 142: 3398-3410.
PubMed
3) Costa A, et al. Postmalaria neurologic syndrome associated with neurexin-3 α anti-bodies. Neurol Neuroimmunol Neuroinflamm. 2017; 4: e392.
 
3) Rauschenberger V, et al. Glycine Receptor Autoantibodies Impair Receptor Function and Induce Motor Dysfunction. Ann Neurol. 2020; 88: 544-561.
PubMed
4) Hutchinson M, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008; 71: 1291-1292.
PubMed
5) Carvajal-Gonzalez A, et al. Glycine receptor antibodies in PERM and related syn-dromes: characteristics, clinical features and outcomes. Brain. 2014; 137: 2178-2192.
 
P.333 掲載の参考文献
1) Ruiz-Garcia R, et al. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol Neuroimmunol Neuroinflamm 2020; 7 :e658
PubMed
2) Yu LJ, et al. Metabotropic glutamate receptors in cancer. Neuropharmacology 2017; 115: 193-202.
PubMed
P.334 掲載の参考文献
1) Beaulieu JM, et al. The physiology, signaling, and pharmacology of dopamine recep-tors. Pharmacol Rev. 2011; 63: 182-217.
 
2) Sinmaz N, et al. Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders. Acta Neuropathol Commun. 2016; 4: 126.
PubMed
3) Dale RC, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012; 135: 3453-3468.
PubMed
4) Pawela C, et al. The neuropsychological proThle of children with basal ganglia enceph-alitis: a case series. Dev Med Child Neurol. 2017; 59: 445-448.
 
P.335 掲載の参考文献
1) Landa J, et al. Encephalitis with Autoantibodies against the Glutamate Kainate Recep-tors GluK2. Ann Neurol 2021; 90: 101-1017.
 
1) Yaguchi H, et al. IdentiThcation of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. J Neurol. 2014; 261: 224-226.
 
2) Pinheiro PS, et al. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci 2008; 9: 423-436.
PubMed
2) Borsche M, et al. Sez6l2-antibody-associated progressive cerebellar ataxia: a differen-tial diagnosis of atypical parkinsonism. J Neurol. 2019; 266: 522-524.
 
3) Landa J, et al. Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurol Neuroimmunol Neuroinflamm. 2020; 8: e916.
PubMed
4) Miyazaki T, et al. Disturbance of cerebellar synaptic maturation in mutant mice lack-ing BSRPs, a novel brain-speciThc receptor-like protein family. FEBS Lett. 2006; 580: 4057-4064.
 
5) Yaguchi H, et al. Sez6l2 regulates phosphorylation of ADD and neuritogenesis. Bio-chem Biophys Res Commun. 2017; 494: 234- 241.
 
P.336 掲載の参考文献
1) Scharf M, et al. Neuronal Na+/K+ ATPase is an autoantibody target in paraneoplastic neurologic syndrome. Neurology. 2015; 84: 1673-1679.
PubMed
2) Garcez D, et al. ATP1A3: an unusual antigen to consider in patients with subacute ataxia and vertical gaze palsy. Mult Scler Relat Disord. 2020; 43: 102160.
PubMed
P.337 掲載の参考文献
1) Balint B, et al. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain. 2018; 141: 13-36.
PubMed
P.339 掲載の参考文献
1) Amyes E, et al. Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cere-bellar degeneration. J Neuroimmunol 2001; 114: 259-264.
 
2) Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021; 8(4): e1014.
PubMed
3) Herdlevaer I, et al. Localization of CDR2L and CDR2 in paraneoplastic cerebellar de-generation. Ann Clin Transl Neurol 2020; 7(11): 2231-2242.
 
4) Okano HJ, et al. The cytoplasmic Purkinje onconeural antigen cdr2 down regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev 1999; 15: 2087-2097.
 
5) Greenlee JE, et al. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol 2010; 69: 997-1007.
PubMed
6) Peterson K, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931-1937.
 
7) Shams'ili S, et al. Paraneoplastic cerebellar degeneration associated with antineuro-nal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-1418.
 
8) Key RG, Root JC. Anti-Yo mediated paraneoplastic cerebellar degeneration in the context of breast cancer: a case report and literature review. Psychooncology 2013; 22: 2152-2155.
PubMed
9) Psimaras D, et al. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81: 42-45.
PubMed
10) Gilmore CP, et al. Diffuse cerebellar MR imaging changes in anti-Yo positive para-neoplastic cerebellar degeneration. J Neurol 2010; 257: 490-491.
 
11) Rojas I, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55: 713-715.
PubMed
12) Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo anti-bodies - a review. Ann Clin Transl Neurol 2016; 3: 655-663.
 
P.340 掲載の参考文献
1) Flanagan EP. Paraneoplastic Disorders of the Nervous System. Continuum 2020; 26(6, Neuro-oncology): 1602-1628.
 
2) 酒井 宏一郎. 傍腫瘍性神経症候群: 診断と治療の進歩. II. 病態. 1. 抗神経抗体の役割・認識抗原. 日本内科学会雑誌 2008; 97: 1809-1815.
 
3) Greenlee JE, et al. Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation 2014; 11: 160.
 
4) Graus F, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-1148.
PubMed
P.341 掲載の参考文献
1) Simard C, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm 2020; 7: e699.
PubMed
2) 酒井 宏一郎. 傍腫瘍性神経症候群: 診断と治療の進歩. II. 病態. 1. 抗神経抗体の役割・認識抗原. 日本内科学会雑誌 2008; 97: 1809-1815.
 
P.342 掲載の参考文献
1) Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1014.
PubMed
2) Honnorat J, et al. Antibodies to a subpopulation of glial cells and a 66 kDa devel-opmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61: 270-278.
 
3) Goshima Y, et al. Collapsin induced growth cone collapse mediated by an intracellu-lar protein related to UNC-33. Nature 1995; 376: 509-514.
 
4) Sabater L, et al. Pitfalls in the detection of CV2 (CRMP5) antibodies. J Neuroimmu-nol 2016; 290: 80-83.
 
5) Yu Z, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-re-lated autoimmunity. Ann Neurol 2001; 49: 146-154.
 
6) Ibrahim Ismail I, et al. Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent. Case Rep Neurol 2020; 12: 50-55.
 
7) Vernino S, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51: 625-630.
PubMed
8) Dubey D, et al. Autoimmune CRMP5 neuropathy phenotype and outcome deThned from 105 cases. Neurology 2018; 90: e103-e110.
PubMed
P.343 掲載の参考文献
1) Flanagan EP. Paraneoplastic Disorders of the Nervous System. Continuum 2020; 26: 1602-1628.
PubMed
1) Flanagan EP. Paraneoplastic Disorders of the Nervous System. Continuum 2020; 26: 1602-1628.
PubMed
2) Dalmau J, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-1844.
PubMed
2) Dalmau J, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-1844.
PubMed
P.344 掲載の参考文献
1) Pittock SJ, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005 Jul; 58(1): 96-107.
PubMed
1) Sun X, et al. Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome. J Clin Neurol. 2020; 16: 530-546.
PubMed
2) Sabater L, et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myas-thenic syndrome. Neurology. 2008; 70: 924-928.
 
2) Schlapakow E, et al. Multiple system atrophy mimicry in MRI: Watch out for parane-oplastic rhombencephalitis. J Clin Neurosci. 2020 Jun; 76: 238-240.
 
3) Berger B, et al. Prevalence of anti-SOX1 reactivity in various neurological disorders. J Neurol Sci 2016; 369: 342-346.
PubMed
P.345 掲載の参考文献
1) Baizabal-Carvallo JF. The neurological syndromes associated with glutamic acid de-carboxylase antibodies. J Autoimmun. 2019; 101: 35-47.
 
2) Graus F, et al. GAD antibodies in neurological disorders - insights and challenges. Nat Rev Neurol. 2020; 16: 353-365.
PubMed
3) Fenalti G, et al. Structural biology of the GAD autoantigen. Autoimmun Rev. 2010; 9: 148-152.
PubMed
4) Daif A, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epi-lepsy. Epilepsy Behav. 2018; 80: 331-336.
 
5) Lilleker JB, et al. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: Diag-nostic yield and therapeutic implications. Seizure. 2014; 23: 598-602.
 
P.346 掲載の参考文献
1) Hoftberger R, et al. Carbonic Anhydrase-Related Protein VIII antibodies and parane-oplastic cerebellar degeneration. Neuropathol Appl Neurobiol. 2014; 40: 650-653.
 
2) Prevezianou A, et al. Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies. J Neuroimmunol. 2020; 344: 577242.
 
3) Bataller L, et al. Carbonic anhydrase-related protein VIII: autoantigen in paraneo-plastic cerebellar degeneration. Ann Neurol. 2004; 56: 575-579.
 
4) Aspatwar A, et al. Phylogeny and expression of carbonic anhydrase-related proteins. BMC Mol Biol. 2010; 11: 25.
PubMed
P.347 掲載の参考文献
1) Shelly S, et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm 2019; 6: e612.
PubMed
1) Berzero G, et al. Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies. Neurol Neuroimmunol Neuroinflamm. 2017; 4: e326.
PubMed
2) Miske R, et al. Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2017; 4: e307.
PubMed
2) Hirota J, at. Al. Carbonic anhydrase-related protein is a novel binding protein for ino-sitol 1, 4, 5-trisphosphate receptor type 1. Biochem J 2003, 372: 435-441.
 
3) Honorat JA, et al. Autoimmune septin-5 cerebellar ataxia. Neurol Neuroimmunol Neuroinflamm 2018; 5: e474.
PubMed
3) Jarius S, et al. Inositol 1, 4, 5-trisphosphate receptor type 1 autoantibodies in parane-oplastic and non-paraneoplastic peripheral neuropathy. Journal of Neuroinflamma-tion. 2016; 13: 278.
 
P.348 掲載の参考文献
1) Flanagan EP, et al. Glial Thbrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Ann Neurol 2017; 81: 298-309.
PubMed
2) Kimura A, et al. Clinical characteristics of autoimmune GFAP astrocytopathy. J Neu-roimmunol 2019; 332: 91-98.
 
3) Gravier-Dumonceau A, et al. Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study. Neurology 2022; 98: e653-e668.
PubMed
4) Kunchok A, et al. Autoimmune glial fibrillary acidic protein astrocytopathy. Curr Opin Neurol 2019; 32: 452-458.
PubMed
5) Dubey D, et al. Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 pa-tients in 1 year. J Neuroimmunol 2018; 321: 157-163.
 
P.349 掲載の参考文献
1) Gadoth A, et al. Microtubule-associated protein 1B: Novel paraneoplastic biomarker. Ann Neurol 2017; 81: 266-277.
PubMed
2) Vernino S, et al. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol. 2000; 47: 297-305.
PubMed
P.350 掲載の参考文献
1) McKeon A, et al. Neuronal intermediate Thlament IgGs in CSF: Autoimmune Axonop-athy Biomarkers. Ann Clin Transl Neurol 2021; 8: 425-439.
 
1) Maudes E, et al. Clinical signiThcance of Kelch-like protein 11 antibodiesNeurol Neu-roimmunol Neuroinflamm 2020; 7: e666.
 
2) Larman HB, et al. Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 2011; 29: 535-541.
PubMed
2) Kirkcaldie MTK, et al. The third wave: Intermediate Thlaments in the maturing ner-vous system. Mol Cell Neurosci 2017; 84: 68-76.
 
3) Robson NC, et al. Simultaneous presentation and cross-presentation of immune-stim-ulating complex-associated cognate antigen by antigen-speciThc B cells. Eur J Immu-nol 2008; 38: 1238-1246.
 
P.351 掲載の参考文献
1) Zekeridou A, et al. Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity. Neurology. 2019; 93: e815-e822.
PubMed
2) Xie Z, et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006; 139: 597-607.
PubMed
3) Loughney K, et al. Isolation and characterization of PDE10A, a novel human 3', 5'-cy-clic nucleotide phosphodiesterase. Gene. 1999; 234: 109-117.
 
P.352 掲載の参考文献
1) Darnell RB, et al. Paraneoplastic syndromes. Oxford, New York: Oxford University Press; 2011.
 
2) Ohno H. Clathrin-associated adaptor protein complexes. J. Cell Sci. 2006; 119: 3719-3721.
PubMed
3) Nakamatsu F, et al. Defective function of GABA-containing synaptic vesicles in mice lacking the AP-3B clathrin adaptor. J. Cell Biol. 2004; 167: 293-302.
 
4) Josephe A, et al. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. Neurology. 2019; 93: e954-e963.
 
P.353 掲載の参考文献
1) Muniz-Castrillo S, et al. Distinctive clinical presentation and pathogenic speciThcities of anti-AK5 encephalitis. Brain. 2021; 144: 2709-2721.
PubMed
1) Josephe A, et al. P Autoimmune septin-5 cerebellar ataxia. Neurol Neuroimmunol Neuroinflamm 2018; 5: e474.
 
2) Bartsch I, et al. Deletion of human GP1BB and SEPT5 is associated with Ber-nard-Soulier syndrome, platelet secretion defect, polymicrogyria, and developmental delay. Thromb Haemost 2011; 106: 475-483.
 
2) Van Rompay AR, et al. IdentiThcation of a novel human adenylate kinase. cDNA clon-ing, expression analysis, chromosome localization and characterization of the recom-binant protein. Eur J Biochem. 1999; 261: 509-517.
 
3) Yang YM, et al. Septins regulate developmental switching from microdomain to nan-odomain coupling of Ca (2+) influx to neurotransmitter release at a central synapse. Neuron 2010; 67: 100-115.
 
3) Ren H, et al. The crystal structure of human adenylate kinase 6: An adenylate kinase localized to the cell nucleus. Proc Natl Acad Sci USA. 2005; 102: 303-308.
 
4) Do LD, et al. Characteristics in limbic encephalitis with anti-adenylate kinase 5 auto-antibodies. Neurology. 2017; 88: 514-524.
 
4) Geis C, et al. Stiff person syndrome-associated autoantibodies to amphiphysin medi-ate reduced GABAergic inhibition. Brain 2010; 133: 3166-3180.
 
P.354 掲載の参考文献
1) Mizutani A, et al. Phosphorylation of Homer3 by calcium/calmodulin-dependent kinase II regulates a coupling state of its target molecules in Purkinje cells. J Neurosci. 2008; 28: 5369-5382.
PubMed
2) Mitoma H, et al. Immune-mediated cerebellar ataxias: practical guidelines and thera-peutic challenges. Curr Neuropharmacol. 2019; 17: 33-58.
 
3) Liu M, et al. Neurological Autoimmunity Associated With Homer-3 Antibody. Neu-rol Neuroimmunol Neuroinflamm 2021;8:e1077.
 
P.355 掲載の参考文献
1) Ren H, et al. Paraneoplastic cerebellar degeneration associated with anti-protein ki-nase Cgamma antibodies in a Chinese patient. J Neuroimmunol. 2020 Sep 29; 350: 57740.
 
2) Watanave M, et al. Protein kinase C γ in cerebellar Purkinje cells regulates Ca2+-ac-tivated large-conductance K+ channels and motor coordination. Proc Natl Acad Sci USA. 2022 Feb 15; 119: e2113336119.
 
3) Hoftberger R, et al. Protein kinase C γ antibodies and paraneoplastic cerebellar de-generation. Journal of Neuroimmunology. 2013; 256: 91-93.
 
4) Sabater L, et al. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J. Neurol. Neurosurg. Psychiatry 77; 2006: 1359-1362.
PubMed
P.356 掲載の参考文献
1) Zekeridou A, et al. Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachs-hund Homolog 1. Ann Neurol. 2022 May; 91: 670-675.
 
2) Chan KH, et al. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-re-lated autoimmunity. Ann Neurol. 2001 Sep; 50: 301-311.
 

書評

最近チェックした商品履歴

Loading...